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DNA neither cares nor knows. DNA just is.  
And we dance to its music. 
 
                                                                       -Richard Dawkins  
  
  
  
Next Generation Sequencing for Measurable Residual 
Disease Detection in Acute Myeloid Leukemia 
Erik Delsing Malmberg 
Department of Laboratory Medicine, Institute of Biomedicine 
Sahlgrenska Academy, University of Gothenburg 
Gothenburg, Sweden 
ABSTRACT 
Acute myeloid leukemia (AML) is the most common form of acute leukemia and 
generally associated with a poor prognosis. For both children and adults, the 
treatment is based on chemotherapy. Allogeneic hematopoietic stem cell transplant 
(alloHCT) is reserved for patients with intermediate or high risk of relapse, due to its 
associated risks. The initial response to treatment is a very important prognostic 
factor. The response is determined by the amount of residual leukemic cells in the 
bone marrow during treatment – measurable residual disease (MRD). The methods 
currently used for MRD analysis have drawbacks in terms of sensitivity and/or 
applicability. The work included in this thesis focused on the development, validation 
and investigation of the clinical applicability of a next generation sequencing based 
strategy for MRD analysis. The strategy was based on identification of leukemia-
specific mutations, present at diagnosis and suitable for MRD, using exome 
sequencing. These mutations were subsequently quantified in follow-up samples 
using an amplicon based sequencing method, targeted deep sequencing. The study 
samples comprised of blood and bone marrow collected at diagnosis, during follow-
up, and at relapse from adults and children with AML. As proof-of-principle, we 
showed in paper I that exome-sequencing could be used for identification of 
leukemia-specific mutations at diagnosis and that targeted deep sequencing of these 
mutations in follow-up samples could be used for patient-tailored MRD analysis. 
Paper II showed that targeted deep sequencing of single nucleotide variations (SNVs) 
for patient-tailored MRD analysis was accurate with good reproducibility and 
sensitivity meeting the consensus criterion for molecular MRD analysis (<0.1% 
leukemic cells). Paper III showed that measurable levels of recurrent NPM1 
insertions after alloHCT, analyzed with targeted deep sequencing were associated 
with higher risk of relapse and worse overall survival as compared to non-detectable 
levels. Paper IV showed that targeted deep sequencing of SNVs for patient-tailored 
MRD analysis in peripheral blood could detect increasing mutation burden before 
hematological relapse in children. In conclusion, the results show that targeted deep 
sequencing of leukemia-specific mutations is an applicable tool for MRD analysis, 
enabling molecular surveillance for virtually all AML patients. The method could 
provide better support for treatment decisions and thereby chances for improved 
prognosis in AML. 
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 SAMMANFATTNING 
Akut myeloisk leukemi (AML) är den vanligaste formen av akut leukemi och 
drabbar årligen cirka 50 personer i Västra Götalandsregionen, varav ungefär 
en tiondel är barn. Prognosen är oftast dålig, där femårs-överlevnaden för 
vuxna som insjuknar i medianåldern (72år) är cirka 45%. Hos barn är AML 
mindre vanligt förekommande, men är den form av leukemi som har sämst 
prognos med en återfallsfrekvens på cirka 40% och total överlevnad på 70%. 
Hos både barn och vuxna bygger behandlingen på cytostatika. Endast 
patienter som bedöms ha en överhängande risk för återfall behandlas med 
efterföljande benmärgstransplantation. Detta eftersom 
benmärgstransplantation är förenad med en väsentlig risk för 
behandlingsrelaterad död och sena biverkningar. Patientens svar på den 
initiala behandlingen är en viktig faktor i beslut om denna behandling. 
Flödescytometri är den metod som huvudsakligen används för påvisande av 
små mängder kvarvarande leukemiceller, Measurable Residual Disease - 
MRD. Kvantitativ PCR kan användas för den andel AML patienter som har 
vanliga genetiska avvikelser och för vilka en analysmetod finns tillgänglig. 
Båda dessa metoder har nackdelar som gör att de inte går att använda för alla 
patienter.  
I detta avhandlingsarbete har vi därför utvecklat, optimerat och testat den 
kliniska användbarheten av en metod för patient-specifik analys av MRD, 
baserad på nya generationens sekvenseringsteknik. I prov från 
diagnostillfället användes flödescytometri för att sortera patienteras 
leukemiceller från friska blodceller. Sedan analyserades arvsmassan från de 
sjuka respektive de friska cellerna separat med exomsekvensering. På detta 
sätt kunde mutationer som var specifika för varje patients leukemiceller 
identifieras.  Utvalda mutationer användes sedan som markörer för att 
analysera kvarvarande mängder leukemiceller i uppföljningsprov med en 
metod som kallas riktad djupsekvensering. Vid riktad djupsekvensering kan 
förekomst av en specifik mutation i ett prov undersökas med hög känslighet. 
I delarbete I visade vi att leukemi-specifika mutationer kan identifieras med 
exomsekvensering i majoriteten av AML-fall vid diagnos och att dessa 
mutationer kan användas för skräddarsydd analys av MRD. I delarbete II 
visade vi att metoden har god riktighet och precision. Metoden användes för 
analys av benmärgsprov från patienter med AML under behandling och gav 
överensstämmande resultat, med högre känslighet än för MRD-analys utförd 
med flödescytometri. För benmärgsprov med MRD-nivåer >0,1% kunde 
mutationerna även påvisas i blodprov tagna vid samma tillfälle. I delarbete III 
visade vi att påvisande av muterad NPM1-gen med riktad djupsekvensering 
hos AML patienter som genomgått benmärgstransplantation, är associerat 
med högre risk för återfall och sämre överlevnad. Detta samband var 
oberoende av andra kända riskfaktorer. I delarbete IV kunde vi påvisa 
leukemi-specifika punktmutationer i blod hos majoriteten av barn som 
genomgått behandling för AML innan kliniskt återfall. Tidig upptäckt av 
återfall skulle kunna leda till bättre respons på insatt behandling och 
förbättrad överlevnad. 
Sammanfattningsvis ger metoden möjlighet till analys av behandlingssvar 
och monitorering för patienter med AML som idag inte kan följas med 
konventionella metoder. 
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1 INTRODUCTION 
 
1.1 DNA, MUTATIONS & MALIGNANT 
TRANSFORMATION 
 
The capacity to blunder slightly is the real marvel of DNA. Without this special 
attribute, we would still be anaerobic bacteria and there would be no music.  
                    -Lewis Thomas,                                             
                    The Lives of a Cell, 1974 
 
1.1.1 THE DNA HELIX 
Nucleic acids, i.e. DNA or RNA, are essential components of all known life. 
Multicellular organisms, including human beings, carry a copy of the same 
DNA in almost all cells throughout the body. Residing within the nuclei of 
eukaryotic cells, DNA constitutes the blueprint for protein production and 
regulation. The DNA molecule consists of a sugar backbone and a sequence 
of four molecules, nucleotides: adenine (A), guanine (G), cytosine (C) and 
thymine (T) (Figure 1). Due to their chemical properties, adenine is always 
paired with thymine, and cytosine with guanine on the opposite strand. 
During the process of transcription, the DNA sequence is transcribed into 
single stranded messenger RNA (mRNA) which in turn is translated into a 
chain of amino acids in the cell cytoplasm. These chains of amino acids (i.e. 
proteins) execute a majority of the processes necessary for cell homeostasis. 
The DNA has secondary and tertiary structure forming chromatin and 
chromosomes. In total, the human genome consists of over 3 billion base 
pairs dispersed over 46 chromosomes, constituting approximately 20.000 
protein-coding genes and additionally equally many non-coding genes 
(ensembl.org). A common definition of the gene is a sequence of DNA which 
codes for the production of a protein, isoforms of a protein or non-coding 
RNA (1). 
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Figure 1. Illustrated is the DNA-helix residing within the cell nucleus. The DNA is densely 
wrapped around proteins, forming chromatin, the constituent of our chromosomes. Image 
from OpenClipart-Vectors, Pixabay. 
 
1.1.2 MUTATIONS – ALTERATIONS IN THE DNA 
SEQUENCE 
The double stranded nature of the DNA helix allows copying, which is the 
fundamental basis for cell division and reproduction. At every cell division 
the DNA helix is duplicated through DNA replication, a truly marvelous 
endeavor. Error correction processes in the cell such as exonuclease activity 
of the DNA polymerase and mismatch  repair, result in an error rate of one 
mistake in every 109 bases copied (2). Hence, copying errors are introduced 
in virtually every cell division. The DNA molecule is also exposed to insults 
from chemical reactions in the cell and potentially from external stimuli such 
as ionizing radiation and chemical mutagens, leading to alterations in the 
nucleotide sequence. The consequence of the alteration is dependent on 
mutation type, on where in the DNA sequence the mutation occurs and in 
what type of cell. A conversion from one nucleotide to another is referred to 
as a single nucleotide variation (SNV). If the SNV occurs in a protein coding 
sequence, possible outcomes at the protein level include truncation of the 
protein (nonsense mutation), exchange of one amino acid (missense mutation, 
classified as conservative if amino acid polarity is retained) or no change at 
Erik Delsing Malmberg 
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all in the chain of amino acids (silent mutation) (Figure 2A). Changes that are 
more dramatic can arise in the genome through insertions or deletions of 
several nucleotides. Unless the inserted or deleted sequence is a multiple of 
three, these mutations will cause a reading frameshift of the DNA code. 
Other major changes, recurrently involved in hematological malignancies, 
include translocations and inversions (Figure 2B). For example, the 
translocation of a proto-oncogene to a site with an adjacent active promotor 
results in increased expression of the oncogenic protein. Translocations could 
also lead to the creation of aberrant non-native proteins with oncogenic 
properties.  
 
 
Figure 2. The different effects of a single nucleotide variation are exemplified in (A). 
Chromosomal rearrangements as depicted in (B) are recurrent events in neoplastic cells. 
Creator of (B) YassineMrabet, Wikimedia commons, Creative Commons CC0. Modified. 
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1.1.3 MALIGNANT TRANSFORMATION 
Random mutations accumulate in our genomes throughout life due to 
replication errors during cell division and exposure to mutagens. Mutations in 
regions of the genome that govern cell proliferation, survival and apoptosis, 
so called proto-oncogenes and tumor suppressor genes, can eventually lead to 
the development of a neoplastic cell. Such a cell has acquired characteristic 
traits including, but not restricted to, independence from external signaling, 
resistance to programmed cell death, genome instability, infinite cell division 
and metastatic potential (3). This renegade cell will give rise to progeny that 
propagates without consideration of neighboring tissue. Some genes (and 
their respective gene product) have exceptional importance for counteracting 
neoplastic transformation. One such example is the tumor suppressor gene 
TP53, which is recurrently mutated to a certain degree in the majority of 
malignant diseases. A mutation leading to dysregulation of the normal DNA 
repair and pro-apoptotic response of TP53 is a serious step toward malignant 
transformation. Other recurrent genetic lesions are more disease specific and 
can in fact be used as diagnostic criteria, e.g. the t(9;22)(q34;q11) reciprocal 
translocation in chronic myelogenous leukemia (CML). This translocation 
results in creation of the oncogenic BCR-ABL1 fusion protein, a 
constitutively active tyrosine kinase which accelerates cell proliferation.  
The successive transformation from normal to neoplastic cell requires several 
mutations with activating effects on proto-oncogenes and inhibiting effects 
on tumor suppressor genes. Almost every case of malignant disease is unique 
in terms of its mutation profile, but mutations in certain genes and even in the 
same exact genomic positions are recurrent within each category of 
malignancies. The order in which these recurring mutations are acquired also 
seems to be of importance for the neoplastic process as similarities in 
mutation type acquisition order are found between cases of the same disease 
(for acute myeloid leukemia (AML) described later in section Recurrent 
mutations in AML & pattern of mutation acquisition). 
1.1.4 NEXT GENERATION SEQUENCING 
Next generation sequencing (NGS), sometimes referred to as Massively 
Parallel Sequencing (MPS), constitutes a number of different sequencing 
techniques where millions of DNA (or RNA) strands are sequenced 
separately and simultaneously. This is in contrast to Sanger sequencing 
where usually only one region of the genome can be sequenced at a time and 
the result is a consensus sequence. There are a number of different producers 
and platforms available for NGS, using different approaches for sequencing. 
This sequencing revolution has generated possibilities to sequence whole 
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exomes, genomes or transcriptomes in a single sequencing run, as well as the 
possibility to interrogate shorter genomic regions at very high resolution. In 
the surge of these high-throughput methods, databases collecting genomic 
data from different disease categories, e.g. for cancer genomes, have become 
important tools for scientists as larger genomic materials now can be studied. 
The NGS techniques have accelerated the identification of new mutated 
genes important in pathological processes as well as genes of prognostic 
importance. 
Although used for research purposes during many years, the potential of 
NGS-based analyses for clinical use has now been widely recognized. 
Currently efforts are made to introduce different NGS assays for several 
clinical questions in Sweden, including hereditary diseases, microbiology and 
cancer diagnostics. For AML, a commercial targeted panel of 54 genes 
frequently mutated in myeloid malignancies is available for identification of 
prognostic markers and has been added as a recommended analysis in the 
2018 Swedish national guidelines for treatment of AML. 
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1.2 ACUTE MYELOID LEUKEMIA (AML) & 
LEUKEMOGENESIS 
 
The pus corpuscles […] were found in the blood throughout the system. 
-John Hughes Bennett,                                                
Case of hypertrophy of the spleen and liver, which 
death took place from suppuration of the blood, 1845 
 
1.2.1 AML EPIDEMIOLOGY 
AML is the most common form of acute leukemia in adults, with a 
worldwide incidence of 2.5 cases per 100,000 persons per year with a modest 
male predominance. The prognosis is generally poor, with the exception of 
the subtype acute promyelocytic leukemia (APL) which entails a good 
prognosis. Data from the Swedish Acute Leukemia Registry, including 2,767 
patients diagnosed between years 1997-2005(APL cases excluded), showed 
highest incidence of AML in ages 80-85 and a median age 72 years. At this 
age, the 5-year overall survival (OS) was 45% for patients fit for intense 
treatment (4). The corresponding 5-year OS for patients <50 years was 55%.  
AML constitutes approximately just 15-20% of all childhood leukemia cases 
but confers a worse prognosis compared to the more common acute 
lymphoblastic leukemia (ALL) (5).  In a Nordic pediatric AML population, 
treated on the Nordic Society for Paediatric Haematology and Oncology 
(NOPHO) AML 2004 protocol, a 3-year OS of 69% was reported (6).  
1.2.2 NORMAL HEMATOPOIESIS & AML 
PATHOLOGY 
Blood has historically been viewed as the essence of life, and rightfully so. 
Our blood is full of specialized cells, carrying out essential functions such as 
oxygen transport, hemostasis and immune response. These cells have a short 
life span and billions of cells need to be replaced every day to maintain 
adequate levels. In the human adult, the blood production (hematopoiesis) 
occurs mainly in the bone marrow of the pelvis, sternum, vertebrae and 
cranium. In the current view of hematopoiesis, the hematopoietic stem cells 
(HSCs), from which all blood cells are derived, reside at the apex of the 
hematopoietic hierarchy. The HSCs have unlimited self-renewal capacity, 
meaning that they through cell division can give rise to new HSCs. The HSC 
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daughter cells can also evolve into committed progenitor cells, which in turn 
mature further into differentiated blood cells. Two of the earliest committed 
cells are the myeloid and lymphoid progenitor cells, from which all the 
myeloid and lymphoid cells are formed respectively (Figure 3). The mature 
myeloid cells consist of granulocytes (neutrophils, basophils and eosinophils) 
and monocytes as well as erythrocytes and thrombocytes. The differentiated 
cells of the lymphoid lineage constitute of small lymphocytes (B and T cells) 
and natural killer (NK) cells. The blood production is rigorously controlled 
by signal molecules; hormones or paracrine molecules, which drive cell 
division and differentiation. The morphological appearance of normal bone 
marrow is shown in Figure 4, left panel. 
Hematological malignancies develop in the wake of deregulated 
hematopoiesis. The development of AML begins in a hematopoietic stem or 
progenitor cell of the myeloid lineage (Figure 3). By acquisition of mutations 
and subsequent malignant transformation, the cell undergoes clonal 
expansion. Although there seems to be a consensus that the ability for AML 
transformation is lost with differentiation, the cell of origin is yet to be 
determined for different types of AML. There are reports suggesting that the 
AML pathogenesis starts already at the level of self-renewing HSCs (7, 8).  
On the other hand, there is data showing the most immature hematopoietic 
cells are protected from leukemic transformation, at least for one specific 
AML subtype (9). The leukemic cells can have morphologic and 
immunophenotypic resemblances with any of the myeloid lineages in AML, 
but myeloblastic and monocytic characteristics are much more common than 
erythroid and megakaryoblastic features. The central attributes of the 
malignant cells are excess proliferation and block in differentiation, leading 
to the accumulation of abnormal immature leukocytes (blasts) primarily in 
bone marrow and blood (Figure 4, right panel). The accumulation of 
leukemic cells results in suppression of normal hematopoiesis (erythropenia, 
thrombocytopenia and neutropenia) and the following characteristic 
symptoms of acute leukemia: fatigue, bleeding and recurrent infections.  
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Figure 3. Illustration of the hierarchy of hematopoiesis. All hematopoietic cells are derived 
from hematopoietic stem cells. Creator A.Rad, Hematopoiesis (human) diagram, Wikimedia 
commons, Creative Commons BY-SA 3.0. Modified. 
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The majority of AML cases are so called de novo AML with a rapid onset of 
symptoms, without evidence of any obvious source of causation. Twenty-five 
percent of patients have a precedent hematological disease 
(myeloproliferative neoplasm (MPN) or myelodysplastic syndrome (MDS)) 
(4). AML development as a consequence of preceding MPN or MDS or 
chemotherapy treatment is often referred to as secondary AML. Other known 
risk factors, such as genetic disorders (e.g. Down’s syndrome and Fanconi 
anemia), ionizing radiation, history of chemotherapy, and benzene exposure 
account for a minor fraction of all AML cases (5).  
  
 
 
 
 
 
 
 
Figure 4. Light microscopy of normal bone marrow (left panel) and Leukemic cells (blasts) in 
acute monoblastic leukemia (right panel). (Photographies courtesy of Benmärgslab, 
Department of Clinical Chemistry, Sahlgrenska University Hospital).  
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1.3 DIAGNOSIS OF AML 
During the diagnostic workup of suspected acute leukemia, numerous 
laboratory analyses are performed. Analysis of bone marrow morphology is 
used to determine relative cell numbers in a differential cell count and the 
morphological characteristics of the cells. To aid in the discrimination 
between AML and differential diagnoses, the leukemic cells are further 
characterized through cytochemical staining, and immunophenotyping using 
flow cytometry. Karyotyping and/or fluorescence in situ hybridization 
(FISH) are used to confirm or exclude the presence of chromosomal 
aberrations.  
The criteria stated below are used to establish the diagnosis of AML.  
Criteria for AML diagnosis 
  
 Leukemic cells (blasts) with myeloid, megakaryocytic or monocytic phenotype (or 
promonocytes) constitute ≥ 20% of nucleated cells in bone marrow or blood 
 
 The first criteria does not have to be fulfilled if any of the AML-specific cytogenetic 
 aberrations t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22)  
or t(15;17)(q22;q21) is present  
 
 The presence of myeloid sarcoma is pathognomonic to AML, and the first criteria is 
 not required to be fulfilled  
 
The genetic heterogeneity of AML, and the resulting differences in risk of 
relapse, demands for sub-classification into separate disease entities. The 
outcome for patients lacking chromosomal aberrations (CN-AML) is also 
diverse. Therefore, in addition to the analyses outlined above, analyses of 
recurrent mutations in the genes NPM1 and CEBPA, necessary for AML 
classification, are done through polymerase chain reaction (PCR) based 
assays. These analyses have recently been complemented with a broader 
mutation analysis using an NGS myeloid gene panel, including RUNX1, as 
AML with mutated RUNX1 has received status of a provisional entity in the 
2016 revision of the WHO classification of AML. Cases of AML are 
primarily classified according to the presence of recurrent cytogenetic or 
genetic aberrations as described in Table 1, whereas cases lacking these are 
classified according to their morphological appearance (AML, not otherwise 
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specified (NOS), Table 1). The AML NOS category corresponds to the 
previously used morphology-based French-American-British (FAB) 
classification of AML. 
 
 
Table 1. WHO Classification of Acute myeloid leukemia (AML) and related 
neoplasms (2016 revision) (10) 
AML with recurrent genetic abnormalities AML, NOS 
     AML with t(8;21)(q22;q22);RUNX1-RUNX1T1      AML with minimal differentiation 
     AML with inv(16)(p13q22) or t(16;16)(p13;q22);CBFB-MYH11      AML without maturation 
     APL with t(15;17)(q22;q21); PML-RARA      AML with maturation 
     AML with t(9;11)(p21;q23);MLLT3-KMT2A      Acute myelomonocytic leukemia 
     AML with t(6;9)(p23;q34);DEK-NUP214      Acute monoblastic/monocytic leukemia 
     AML with inv(3)(q21q26) or t(3;3)(q21;q26); GATA2- MECOM      Pure erythroid leukemia 
     AML (megakaryoblastic) with t(1;22)(p13;q13);RBM15-MKL1      Acute megakaryoblastic leukemia 
     Provisional entity: AML with BCR-ABL1      Acute basophilic leukemia 
     AML with mutated NPM1      Acute panmyelosis with myelofibrosis 
     AML with biallelic mutations of CEBPA Myeloid sarcoma 
     Provisional entity: AML with mutated RUNX1 Myeloid proliferations related to Down syndrome 
AML with myelodysplasia-related changes      Transient abnormal myelopoiesis (TAM) 
Therapy-related myeloid neoplasms      Myeloid leukemia associated with Down syndrome 
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1.4 RECURRENT GENETIC ABERRATIONS IN 
AML & PATTERN OF MUTATION 
ACQUISITION 
AML is a heterogeneous disease entity. Through extensive genetic analyses it 
has been shown that adult AML genomes on average contain only 13 
mutations in genes of which 5 recurrently mutated in AML (11). This 
suggests that AML genomes are less prone to genomic instability compared 
to most malignancies in adults (12). The mutational spectrum is different in 
adult and childhood AML. Chromosomal translocations, e.g. t(8;21) 
(RUNX1-RUNX1T1), inv(16) (&%)ȕ-MYH11) and KMT2A rearrangements 
are more common in children (13) (Figure 5A). The chromosomal 
translocations correlate with age, where KMT2A rearrangements are found in 
infants and inv(16) (CBFB-MYH11) and t(8;21) (RUNX1-RUNX1T1) 
generally occur in older children (14). In addition to chromosomal 
translocations, specific gene mutations are also recurrent in AML. Mutations 
in NPM1 and FLT3 occur frequently and for NPM1 more often in adults (15) 
(Figure 5B). Mutations in genes encoding epigenetic regulation, e.g. 
DNMT3A and IDH1/2 are also common in adult AML but are rarely found in 
childhood AML. Some mutations have been described to be more common in 
childhood AML, including mutations in NRAS and WT1.  
 
 
 
 
 
 
 
 
 
Figure 5. The prevalence of recurrent chromosomal rearrangements among different age 
groups is shown in (A) and a list of the most frequently mutated genes in descending order is 
presented in (B). (Based on data from Grimwade & Freeman, Blood 2014 (13) and Bolouri et 
al., Nat. Med. 2018(15)).  
A) B) 
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*Frequency in adult AML as reported by Ley et al., NEJM, 2013 (11). Each AML case 
could have multiple genetic aberrations belonging to different functional groups.  
1.4.1 FUNCTIONAL GROUPING OF RECURRENT 
MUTATIONS 
Due to the characteristic traits of increased proliferation and block in 
differentiation, a persisting view of AML leukemogenesis is the two-hit 
hypothesis proposed by Gilliland & Griffin (16). In this view, mutations 
belonging to two different categories (class I and II) with co-operating effects 
are needed for AML development. Class II mutations include mutations in 
genes encoding myeloid transcription factors with following impairment of 
hematopoietic differentiation (17). Class I mutations affecting tyrosine 
kinases and downstream pathways contribute to excess proliferation and 
evasion of apoptosis (e.g. FLT3, KIT, KRAS, NRAS). However, gene 
mutations in other pathways have also been shown to be of importance for 
AML development. One major group is the genes involved in epigenetic 
regulation, including mutations in genes encoding chromatin modifiers and 
genes involved in DNA methylation. Two other minor groups constitute 
mutations in cohesin complex and spliceosome genes. Spliceosome 
mutations seem to be related to myelodysplasia and are therefore found in 
AML secondary to MDS, but are also rather frequent in elderly with AML 
(18, 19). Mutations in the cohesin complex are quite uncommon and have a 
strong association to NPM1 mutations. Interestingly mutations in the DNA 
methylation genes IDH1, IDH2 and TET2 occur in a mutually exclusive 
manner, which also is the case for mutations in cohesin complex and 
spliceosome genes as well as transcription factor fusions (11, 20-22). This 
implicates that several hits in the same pathway do not confer survival 
benefits. Genes involved in AML pathogenesis in adults are listed in Table 2 
and classified according to functional groups. 
Table 2. Genes involved in AML pathogenesis 
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Chromosomal rearrangements and mutations recurrent in AML that are 
central to this thesis are concisely described below. 
1.4.2 MUTATIONS IN NUCLEOPHOSMIN1 (NPM1) 
Mutations in NPM1 are among the most common genetic aberrations in 
AML, and occur in approximately 30% of adult AML and 7% of childhood 
AML (13). The NPM1 gene, located  on chromosome 5, encodes a 
phosphoprotein that normally exists in the cell nucleus where it has multiple 
functions, e.g. functions linked to DNA methylation, chromatin structure and 
regulation of the ARF-p53 tumor suppressor pathway (23). The 
predominating mutations are the four base pair insertions type A 
(c.863_864insTCTG, 80%), type B (c.863_864insCATG, 9%) and type D 
(c.863_864insCCTG, 3%), all resulting in the same frameshift (24). 
Frameshift mutations in NPM1 exon 12 cause a modification in the protein’s 
C-terminus, which elongates it and substitutes one or two tryptophan 
residues, leading to a translocation of the protein from the nucleus to the 
cytoplasm. The translocation causes a loss of the normal function of NPM1 
and is considered to contribute to leukemogenesis (25). The recurrent 
mutations in NPM1 confer favorable risk, unless there is a concurrent FLT3-
ITD. 
1.4.3 INTERNAL TANDEM DUPLICATIONS OF FMS-LIKE 
TYROSINE KINASE 3 (FLT3-ITD) 
The prevalence of FLT3-ITD is also high in AML and is found in 
approximately 25% of cases (26). The FLT3 gene encodes a receptor tyrosine 
kinase, present on hematopoietic stem and progenitor cells, which have a 
central role in the regulation of normal hematopoiesis (27). In-frame internal 
tandem duplications (ITDs) in this gene occur in the region coding for the 
juxtamembrane domain, and may vary from 3 to over 400bp in length. The 
ITD mutation leads to constitutive activation of the receptor, independent of 
the ligand (28). Presence of the mutation is associated with inferior outcome 
in both children and adults (29, 30). The allelic frequency of the FLT3-ITD is 
also reported to be important for prognosis. According to the 2017 ELN 
recommendations, patients with allelic ratio ≥0.5 should be stratified to 
adverse risk. Patients with mutated NPM1 and an FLT3-ITD allelic ratio <0.5 
should be considered to be at favorable risk. In the absence of a NPM1 
mutation, the presence of FLT3-ITD is associated with inferior outcome than 
for FLT3 wildtype patients, regardless of allelic ratio (31). A recent study 
however reported the conflicting results that NPM1 mutation and low allelic 
ratio was not associated with favorable outcome (32). 
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1.4.4 KMT2A (11q23) FUSIONS 
Translocations involving the KMT2A (Lysine(K)-specific Methyl-Transferase 
2A, previously known as MLL) gene occur more often in childhood than adult 
AML. KMT2A rearranged AML is associated with monoblastic or 
myelomonocytic features (33). The KMT2A gene encodes a histone 
methyltransferase involved in epigenetic gene regulation during early 
development and hematopoiesis. A multitude of different fusion partners 
have been described, but only six are frequently found in AML of which 
KMT2A-MLLT3 t(9;11)(p22;q23) is the most common (34). Translocation 
leads to deregulation of the KMT2A target genes (35). AML with KMT2A 
rearrangements are generally associated with poor prognosis and AML with 
KMT2A fusions seem to need fewer cooperating mutations than other AML-
subgroups, suggesting a strong leukemogenic potential (11). A large study on 
pediatric AML confirmed that most KMT2A-rearrangements confer a poor 
prognosis, but also showed that the prognosis depends on the translocation 
partner (36). 
1.4.5 CORE BINDING FACTOR AML 
Core binding factor (CBF) AML includes two recurrent cytogenetic 
aberrations; t(8;21)(q22;q22) RUNX1-RUNX1T1 and 
inv(16)(p13q22)/t(16;16)(p13;q22) CBFB-MYH11. These translocations are 
also more frequent in childhood AML (18% of pediatric cases) than in adult 
AML (12% of adult cases), and identification of either of these two 
translocations is sufficient for diagnosis of AML (13). The core binding 
factors are transcriptional regulators consisting of two subunits, one alfa 
subunit which is DNA-binding and one beta subunit which is stabilizing. The 
beta subunit is encoded by CBFB and the alfa subunit by one of three 
different genes, of which one is RUNX1. The CBF dimer that is composed of 
RUNX1 and CBFB is a transcriptional regulator of genes involved in 
myeloid differentiation (37). The RUNX1-RUNXT1 fusion protein excerpts 
a dominant negative effect on the normal RUNX1 protein (38). The CBFB-
MYH11 fusion protein forms filament, molecular high weight structures, 
which are thought to bind RUNX1 and thereby prevent nuclear entrance (39). 
CBF AML is generally associated with a favorable prognosis.  
1.4.6 PATTERN OF MUTATION ACQUISITION 
AML is genetically heterogeneous and hence the pattern of mutation 
acquisition is diverse.  Two recent studies investigated the presence of 
somatic mutations in peripheral blood of healthy individuals who several 
years later developed AML (40, 41). This enabled identification of a 
premalignant mutational landscape, many years before diagnosis. One study 
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describes that individuals developing AML had more mutations and greater 
clonal complexity than age-matched controls (median 9.6 years before AML 
diagnosis). Mutations in genes DNMT3A, IDH1, IDH2, TET2, TP53 and 
spliceosome genes were associated with increased risk of AML development, 
where all cases with TP53, IDH1 and IDH2 developed AML (40). Similarly, 
blood samples collected on average 6.3 years before AML diagnosis were 
analyzed in another study (41). Here it was reported that mutations in 
DNMT3A, IDH2, TET2, TP53 and spliceosome genes (among others) were 
significantly enriched in cases that developed AML as compared to controls. 
Mutations in TP53 and U2AF conferred a relatively high risk of AML 
development, whereas mutations in e.g. DNMT3A and TET2 were associated 
with lower risk. No mutations in NPM1 or any FLT3-ITDs were reported, in 
agreement with previous reports that mutations in these genes are late events 
in AML development (7, 8, 42), nor any mutations in CEBPA. These reports 
suggest that the stepwise evolution of AML occurs during a long period of 
time. 
An earlier study showed that mutations in chromatin modifiers, genes 
involved in DNA methylation and cohesin complex genes as well as 
transcription factor fusions are early events in AML development compared 
to mutations in genes leading to activated signaling (7). DNMT3A-mutations 
have been reported to be retained in some patients who lost the NPM1 
mutation at relapse, suggesting that acquisition of DNMT3A mutations 
precede NPM1 mutations (43). Several studies have further showed the 
persistence of DNMT3A and IDH1/IDH2 mutations after treatment, 
suggesting that these mutations exist also in pre-leukemic cells (44-46). 
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1.5 RISK STRATIFICATION & TREATMENT IN 
AML 
 
He will manage the cure best who has foreseen what is to happen from the present 
state of matters. 
-Hippocrates                                             
The book of prognostics, Part 1,       
400 BC. 
 
1.5.1 TREATMENT 
The treatment protocols for both childhood and adult AML are based on 
chemotherapy (usually a combination of cytarabine and an anthracycline), 
administered in cycles. The first course/s (induction therapy) is/are given 
with the intent to induce complete remission (CR), i.e. morphologically 
normal bone marrow and restored peripheral blood cell counts.   
 
Definition of complete remission (CR) according to the 2017 European LeukemiaNet 
(ELN) recommendations: 
 
Bone marrow blasts <5%, absence of circulating blasts and blasts with Auer rods, absence 
of extramedullary disease, absolute neutrophil count ≥ 1.0x109/L, platelet count ≥ 
100x109/L, independence of red blood cell transfusions (47). 
 
The majority of patients under 60 years of age, 70-80%, enter CR from 
induction chemotherapy (48, 49). However, after achievement of CR 
additional treatment is needed to eradicate remaining leukemic cells 
(consolidation treatment) for prevention of early relapse. Adult patients at 
low risk of relapse obtain 2-3 consolidation courses of chemotherapy, 
whereas fit patients at intermediate or high risk of relapse are eligible for 
allogeneic hematopoietic stem cell transplant (alloHCT). Children with AML 
are stratified to standard or high risk and standard risk patients receive three 
courses of conventional chemotherapy after induction, whereas high risk 
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patients are assigned to alloHCT according to the NOPHO-DBH AML-2012 
treatment protocol (Nordic Society of Paediatric Haematology and Oncology, 
EUdract number 2012-002934-35). 
The aim of alloHCT is to eradicate the majority of all blood cells, including 
the malignant cells, using high-dose chemotherapy (conditioning) and 
thereafter restore the hematopoietic system.  Patients undergoing alloHCT 
receive an intense conditioning therapy following a transfusion of 
hematopoietic stem cells from an HLA-matched sibling or unrelated donor, 
or in some instances a haplo-identical family member. Patients at low risk of 
relapse are not eligible for alloHCT as the intervention is associated with 
both direct (organ toxicity and increased risk of infections) and late onset 
complications (infertility and secondary malignancies) as well as a high 
mortality rate (50). In addition to the anti-leukemic effects of the 
chemotherapy administered as conditioning, the immunological response 
associated with alloHCT has potent effects. The donor cells (graft) attack the 
remaining leukemic cells through the Graft-versus-Leukemia (GvL) effect. 
This positive GvL effect can be further exploited through modulation of 
immunosuppressive drugs or by donor lymphocyte infusions (DLIs) after 
transplantation. Another consequence of alloHCT is the immunological 
response that occurs between the donor (graft) and recipient cells (host), 
causing the unwanted acute and sometimes chronic effects of Graft-versus-
Host Disease (GvDH). In fulminant GvHD, the donor cells attack the host 
organs, causing painful immune-mediated mucositis, enteritis, skin rashes 
and potentially severe damage to liver and lungs. To reduce the risk of 
GvHD, the patient can be transplanted with T lymphocyte depleted donor 
cells. Other measures include administration of antithymocyte globulin 
(ATG) as a component of the conditioning regimen and post-transplant 
administration of potent immunosuppressive drugs.  
1.5.2 RISK STRATIFICATION IN ADULT AML 
Risk stratification in AML is performed to identify groups of patients who 
differ in chance of achieving CR and risk of relapse after treatment. This in 
turn determines if the individual patient should be considered for treatment 
with alloHCT.  There are numerous variables determining the risk of relapse 
for patients with AML. These can be divided into disease-related factors, 
such as genetic aberrations and treatment response, and patient-related factors 
such as age and comorbidity. 
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Risk stratification in adults with AML is primarily based on the prognostic 
implications of genetic aberrations detected at diagnosis (Table 3). Relapse 
risk in adult AML can also be predicted from the patient’s response to 
treatment, independent of the genetic aberrations detected at diagnosis. 
Inefficient response to induction treatment (>15% blasts after course 1 or that 
>2 courses were needed to achieve remission) or presence of low amount of 
residual leukemic cells, minimal/measurable residual disease (MRD), 
duringmorphological CR are adverse risk factors (51-53). A history of 
antecedent hematological disease (MDS, MPN) or treatment with chemo- or 
radiotherapy not related to AML renders a higher risk of relapse as compared 
to de novo AML (54, 55). The frequencies of adverse risk cytogenetic 
aberrations are higher in these groups, but the risk of relapse varies based on 
cytogenetic aberrations similarly as for de novo AML (56). There is an 
increased incidence of unfavorable cytogenetic aberrations and antecedent 
hematological disorders in older patients. Age is however an important 
negative prognostic factor independent of cytogenetic aberrations, as 
treatment outcome declines with age in all subgroups in patients >50 years 
old (57, 58). Considering the dismal prognosis and the high mortality 
associated with alloHCT in the elderly, this treatment is seldom justified for 
patients > 70 years. Severe comorbidity with increasing prevalence in the 
elderly, i.e. heart, lung or kidney dysfunction, increases the risk of therapy 
related complications and early death. However, impaired performance status 
has been shown to negatively impact early death rate at all ages, and most 
patients < 80 years should be considered fit for standard intensity 
chemotherapy (4). 
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Table 3. Adapt. from 2017 European LeukemiaNet 
risk stratification by genetics (47) 
Risk 
category Genetic abnormality 
Favorable t(8;21)(q22;q22);RUNX1-RUNX1T1                                                   
inv(16)(p13q22) or t(16;16)(p13;q22);CBFβ-MYH11                            
Mutated NPM1 without FLT3-ITD or with FLT3low(a)                                   
Biallelic mutated CEBPA  
Intermediate Mutated NPM1 and FLT3-ITDhigh(a)                                                                       
Wild-type NPM1 without FLT3-ITD or with FLT3low(a)      
(w/o adverse-risk genetic lesion)                                                            
t(9;11)(p21;q23);MLLT3-KMT2A(b)                                                   
Cytogenetic abnormalities not classified as favorable or 
adverse 
Adverse inv(3)(q21q26) or t(3;3)(q21;q26);GATA2- MECOM 
(EVI1)                                                                   
t(6;9)(p23;q34);DEK-NUP214                                                         
t(v;11q23);KMT2A rearranged                                            
t(9;22)(q34;q11);BCR-ABL1                                                                          
-5q or del(5q); -7;-17/ abn(17p)                                                                 
Complex karyotype(c), monosomal karyotype(d)                                          
Wild-type NPM1 and FLT3-ITDhigh(a)                                                                                                       
Mutated RUNX1(e)                                                                                        
Mutated ASXL1(e)                                                                                         
Mutated TP53 
aLow allelic ratio (<0.5);high allelic ratio (≥0.5).                                                                                           
bThe presence of t(9;11)(p21;q23) takes precedence over rare, concurrent 
adverse-risk gene mutations.                                                                                                                                                                                                                      
cThree or more unrelated chromosome abnormalites in the absence of the 
WHO designated recurring translocations and inversions t(8;21), inv(16), 
t(16;16), t(v;11)(v;q23), t(6;9), inv(3),  t(3;3) or t(9;22).                                                                                                                                      
dDefined by the presence of one single monosomy (excluding loss of X 
and Y) in association with at least one additional monosomy or structural 
chromosome abnormality (excluding core binding factor AML).                                                                                                                                                   
eThese markers should not be used as an adverse prognostic marker if they 
co-occur with favorable-risk AML subtypes. 
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1.5.3 RISK STRATIFICATION IN CHILDHOOD AML 
Risk stratification according to the NOPHO-DBH AML-2012 treatment 
protocol, into standard or high risk of relapse, is based primarily on response 
to treatment evaluated with MRD. The only risk stratifying genetic aberration 
is FLT3-ITD without concurrent NPM1 mutation (high risk), but the presence 
of CBFB-MYH11 inv(16) also guides treatment intensity. Since few genetic 
aberrations have yet been shown to be of value for risk stratification, MRD is 
of even greater importance in children. MRD has been shown to be of 
prognostic value when used to evaluate treatment response after induction 
treatment using multiparameter flow cytometry (MFC), and the result from 
MFC-MRD therefore affects choice of treatment. To be noted, there are other 
genetic and cytogenetic aberrations shown to be of prognostic value in 
childhood AML, some of which are described in the WHO classification, that 
are used for risk stratification in other protocols. These include, among 
others, the favorable markers NPM1 mutation, biallelic mutation in CEBPA 
and RUNX1-RUNX1T1 t(8;21). Adverse marker include -7, -5(or del(5q)), 
GATA2-MECOM inv(3) and several KMT2A rearrangements (59).  
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1.6 MINIMAL (OR MEASURABLE) RESIDUAL 
DISEASE 
 
It is easy to make perfect decisions with perfect information. Medicine asks you to 
make perfect decisions with imperfect information. 
-Siddharta Mukherjee,  
The Laws of Medicine: Field Notes from an 
Uncertain Science, 2015 
 
1.6.1 DEFINITION & IMPORTANCE 
Historically, the only available method to determine treatment response was 
examination of bone marrow morphology with estimation of remaining 
leukemic cells using a light microscope. This method is associated with a 
number of limitations, including the intra-and inter-observer variability and 
that normally only five hundred nucleated cells are examined. Furthermore, 
healthy blasts which constitute a few percent of cells in normal bone marrow 
are difficult to separate morphologically from leukemic cells. Hence, 
leukemic cells less frequent than 1-5% cannot be detected using this method. 
As previously described, a majority of patients achieves CR after induction 
treatment, but this is not a sufficient reduction of the leukemic cells to 
prevent relapse. Morphological assessment of treatment response is thus not 
sensitive enough to detect small amounts of residual leukemic cells of clinical 
importance. Minimal residual disease is defined as residual leukemic cells 
detected during CR (i.e. levels below the resolution of light microscopy). 
This low percentage can still correspond to millions of leukemic cells spread 
throughout the body, and heralds the potential to give rise to relapse (Figure 
6). As MRD negativity is not necessarily equivalent to absence of leukemic 
cells, the term measurable residual disease has been suggested to be more 
appropriate and is gaining acceptance. Sub-microscopic residual leukemic 
cells can now be quantified for prediction of outcome using 
immunophenotypic or molecular markers (60, 61). MRD can be assessed at 
early timepoints (post induction or consolidation treatment) to determine 
treatment response. According to the 2018 Swedish national guidelines for 
treatment of AML, patients who are MRD positive with favorable genetic 
risk should be considered for alloHCT in first remission (CR1). For MRD 
negative patients with intermediate genetic risk and comorbidity, alloHCT 
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could be abstained from. MRD status after alloHCT can be used to identify 
patients with increased relapse risk and therefore guide immunomodulatory 
treatment post-transplant. MRD surveillance can also be used after end of 
treatment for early detection of relapse. 
 
 
 
 
Figure 6. A schematic of the concept of minimal/measurable residual disease, which 
constitutes remaining leukemic cells after treatment below the resolution of the light 
microscope. The left panel illustrates a patient treated with chemotherapy achieving a 
successful eradication of the leukemic cells. The patient in the right panel has low levels of 
remnant leukemic cells after end of treatment, MRD, heralding a relapse.   
 
1.6.2 ESTABLISHED METHODS FOR ANALYSIS OF 
RESIDUAL DISEASE  
1.6.3 FLOW CYTOMETRY 
Flow cytometry is used to measure the optical properties (size and 
complexity) and the protein expression characteristics of cells. To analyze 
protein expression, the cells of interest are labeled by the use of 
fluorochrome-conjugated antibodies targeting cell surface or cytoplasmic 
antigens. The flow cytometer identifies cells that express or lack the antigens 
of interest, when flowing through a single cell lane, using exciting light and 
fluorescence emission detectors. Most cytometers in clinical use have the 
capacity to synchronously analyze ≥ 8 fluorochromes. The ability to measure 
multiple antigens on each cell on thousands of cells per second, have made 
multi-parameter flow cytometry (MFC) important in characterization of 
hematological malignancies, including AML. To achieve comparable results 
between different laboratories, standardized flow cytometer settings, panels 
and protocols are needed. The EuroFlow consortium is one organization that 
develops guidelines to standardize workflows for 8-color flow cytometry 
between laboratories (62, 63). 
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In addition to having an important role in AML diagnostics, MFC is today 
the standard method for analysis of treatment response in AML (MFC-
MRD). The method relies on the possibility to define a leukemia-associated 
immunophenotype (LAIP), distinguishable from normal bone marrow cells, 
to track during follow up. This is performed by identifying cells with 
abnormal patterns of immunophenotypic markers, including over- or under-
expression of antigens, cross-lineage antigen expression and antigens with 
asynchronous expression. It is possible to identify a LAIP in approximately 
90% of all AML cases (13).  Alternatively, the Different-from-Normal 
approach can be used, where the MRD population/s is/are identified in MFC 
spaces normally empty in healthy controls. Using this strategy, identification 
of MRD populations during follow-up is not confined to the aberrant markers 
present at diagnosis. Thus, also markers affected by immunophenotypic shifts 
during treatment will be included. However, the lack of guidelines for how to 
define these empty spaces makes the method difficult to standardize. A 
commonly used cutoff for MRD positivity is 0.1% leukemic cells, as 
recommended by the ELN MRD Working Party (64). To be certain that an 
identified immunophenotypic population is true, it needs to constitute of a 
critical number of events. As the leukemic cells are quantified relative to 
other cells in the sample, the smallest cell population possible to determine 
MRD positive is dependent on the total number of analyzed cells. This limits 
the sensitivity of the method at times during treatment when the bone marrow 
is hypoplastic.  
1.6.4 RT-qPCR 
Another method for MRD analysis is the reverse transcription quantitative 
polymerase chain reaction (RT-qPCR). Here, the expression of AML-specific 
genetic lesions relative to a stable reference gene is analyzed. Through 
conversion of mRNA to complementary DNA (cDNA), RT-qPCR is used for 
gene expression quantification by the use of an ordinary PCR in combination 
with a locus specific fluorescent probe or unspecific DNA stain. Residual 
leukemic cells can be quantified with higher sensitivity using this method 
than with MFC. The sensitivity of the assay depends on the relative 
expression of the fusion-gene in the leukemic cells as compared to the 
expression of a reference gene (e.g. ABL1). Hence, the sensitivity varies 
between different targets (~10-3-10-6) and between patients. RT-qPCR for 
MRD analysis is only applicable to the subgroup of AML cases with 
recurrent chromosomal translocations, found in approximately 50% and 20% 
in childhood and adult AML respectively, such as RUNX1-RUNX1T1 and 
CBFB-MYH11  or recurrent mutations, such as NPM1 (7% of children and 
30% of adults) (13). In an effort to standardize the use of RT-qPCR assays 
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for MRD analysis in AML, the Europe Against Cancer network (EAC) has 
developed protocol recommendations regarding common Taqman probes, 
primers and reference genes (65).     
1.6.5 THE PREDICTIVE ROLE OF MRD ON 
OUTCOME 
1.6.6 HEMATOLOGICAL MALIGNANCIES BESIDES AML 
The use of MRD for risk assessment and therapy modulation in AML, with 
the exception of APL, has been lagging behind the use in ALL and CML (66-
68). For CML, MRD surveillance using RT-qPCR of BCR-ABL1 transcripts 
are used to monitor treatment response at established time points and with set 
MRD cutoff levels guiding choice of therapy (67).  
Regarding ALL, MRD has been shown to be the best predictor of relapse in 
both children and adults (69-73). Flow cytometry and allele-specific 
oligonucleotide (ASO) PCR are routinely applicable MRD methods. The 
ASO-PCR takes advantage of the fact that developing lymphocytes undergo 
genetic rearrangements in immunoglobulin (B cells) and T-cell receptor (T 
cells) genes and that ALL constitutes of a clonal expansion from a single 
lymphoid precursor cell. A randomized control trial (UKALL 2003) showed 
that treatment reduction based on low risk MRD status (measured by ASO-
PCR, MRD cutoff 10-4) at the end of induction therapy is possible for 
children and adolescents with ALL. The same study also investigated 
augmented therapy in MRD high-risk patients with significant effect on 5-
year event-free survival (EFS), but with more adverse events (74). Eckert et 
al. focused on children with relapsed intermediate risk ALL. Patients with 
MRD levels ≥10-3 (measured by ASO-PCR) at the end of induction therapy 
were allocated to alloHCT whereas those with MRD levels <10-3 received 
chemotherapy. A significant increase in EFS was seen in the poor responder 
group as compared tothe preceding protocol (75). In the NOPHO ALL2008 
treatment protocol, MRD levels were used to risk stratify patients (age 1-45 
years) using flow cytometry and ASO-PCR for BCP- and T-ALL 
respectively (76). Patients with residual disease ≥ 5% after induction and/or ≥ 
0.1% after consolidation were eligible for alloHCT. They reported that the 
application of the more aggressive, MRD-guided, pediatric protocol on 
young adults resulted in a better outcome as compared to traditional treatment 
regimens for adults. Modvig et al. analyzed the results from the T-ALL 
patients in the NOPHO ALL2008 protocol where post-induction ASO-PCR 
MRD was used for risk stratification with cutoff 0.1% (77). MFC-MRD and 
ASO-PCR were run in parallel and for cases where no informative result was 
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obtainable from ASO-PCR, MFC-MRD was used for stratification. More 
than 99% of the patients had a marker for MRD assessment when combining 
the two methods. The negative predictive value was 92.2% for MFC-MRD 
and 95.8% for ASO-PCR for levels <0.1%. 
1.6.7 AML 
A considerable number of studies have shown the independent prognostic 
importance of MRD status on relapse risk and overall survival in AML using 
different methods and assessment time points.  
It has been shown that MRD analysis of PML-RARA using RT-qPCR is a 
strong predictor of outcome in APL and that MRD guided preemptive 
therapy can prevent relapse (66). MRD positivity after consolidation 
treatment in APL is therefore used to determine eligibility for alloHCT. 
Further, in case of molecular relapse after end of treatment, early treatment 
intervention should be considered according to the current ELN 
recommendations (78). 
MFC-MRD has shown to be of prognostic value when used to evaluate 
treatment response after induction treatment in both children and adults with 
AML (52, 60, 79, 80). Remission status as determined with MFC is a better 
predictor of outcome in AML than CR as determined with morphology (80-
82).The result from MFC-MRD therefore affects the choice of treatment in 
several current treatment protocols (83, 84). The prognostic importance of 
MFC-MRD in adults has also been established pre- and post alloHCT (85-
87).   
Quantification of MRD using RT-qPCR of the genetic aberrations, RUNX1-
RUNX1T1, CBFB-MYH11, KMT2A-MLLT3 and NPM1, during treatment has 
been shown to be predictive of outcome (61, 88-92). Regarding the alloHCT 
setting, post-transplant MRD-status determined with RT-qPCR of fusion 
transcripts RUNX1-RUNX1T1 and CBFB-MYH11 has been shown to confer 
prognostic significance (93, 94).  Transcript expression levels of the gene 
Wilm’s Tumor 1 (WT1) quantified by RT-qPCR have prognostic value when 
measured before and after alloHCT (95, 96). Finally, MRD analysis using 
RT-qPCR of mutated NPM1 pre- and post-alloHCT has also been shown 
predictive of outcome (25, 97, 98). Although standardized RT-qPCR assays 
are available, MRD based decision making in AML using RT-qPCR has just 
recently been introduced in clinical practice. According to the recently 
published recommendations from the ELN MRD Working Party, molecular 
MRD analysis should be performed in adult patients with APL (PML-RARA), 
AML with CBFB-MYH11 or RUNX1-RUNX1T1 and NPM1 mutated AML. 
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There are however no recommendations from ELN for change in therapy 
based on result. The remaining patients should be monitored with MFC-
MRD. The use of WT1 as MRD marker is not recommended if another 
method is available, due to low sensitivity and specificity (64). 
Recommendations regarding MRD analysis of NPM1 and CBF-AML have in 
line with this been added to the 2018 Swedish national guidelines for 
treatment of AML. 
1.6.8 MRD DIRECTED THERAPY IN AML 
Whether MRD can be used for therapy modulation or preemptive treatment 
for prevention of relapse in AML is still under investigation. Large 
prospective randomized controlled trials showing that treatment interventions 
based on MRD status leads to improved outcome are still lacking. 
1.6.9 THERAPY MODULATION 
In childhood AML, a prospective study used risk stratification based on a 
combination of cytogenetic risk group and MFC-MRD (cutoff 0.1%) after the 
first course of chemotherapy to guide treatment intensification. High-risk 
patients were eligible for alloHCT, whereas low-risk patients received 
chemotherapy only. They compared their results to other recent trials and 
concluded that their strategy could improve outcome in childhood AML (83). 
The current Nordic treatment protocol for childhood AML (NOPHO-DBH 
AML-2012) has adopted this MRD cutoff after induction treatment for 
allocation to the high-risk group. 
Another prospective, but not randomized, study investigated adult patients 
with RUNX1-RUNX1T1, where high-risk patients either failed to achieve 
major molecular response (MMR; defined as > 3-log reduction in fusion 
transcripts compared to pretreatment baseline) after the second consolidation 
treatment or lost MMR status within 6 months. Low risk-patients achieved 
MMR after the consolidation and maintained MMR for 6 months. High risk-
patients were recommended alloHCT whereas low-risk patients were 
recommended continuous chemotherapy/autologous hematopoietic stem cell 
transplant (autoHCT). Due to patients’ bias, a fraction of high-risk patients 
were treated with chemotherapy and a fraction of low-risk patients with 
alloHCT. AlloHCT improved overall survival in high-risk patients but 
impaired the survival of low-risk patients. Low-risk patients treated with 
chemotherapy/autoHCT had a low relapse rate. The authors conclude that 
MRD based treatment stratification may improve the outcome for RUNX1-
RUNX1T1 AML patients in CR1 (99). The 2018 Swedish national guidelines 
for treatment of AML includes MRD based treatment recommendations for 
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patients treated with curative intent, using RT-qPCR for NPM1-mutated and 
CBF-leukemia and MFC-MRD for other cases. 
There are some retrospective studies suggesting that MRD status could be 
used to guide post-remission treatment with alloHCT in adult AML. Qin et 
al. used RT-qPCR of CBFB-MYH11 to analyze MRD after second 
consolidation in AML patients with inv(16) (100). Patients with poor 
molecular response (defined as < 3-log reduction in fusion transcripts 
compared to pretreatment baseline) had significantly increased 3-year DFS 
and OS when treated with alloHCT as compared to treatment with 
chemotherapy or autoHCT. AlloHCT did not improve outcome for patients 
with good molecular response as compared to chemotherapy/autoHCT. 
Balsat et al. showed that adult patients with a less than 4-log reduction of 
mutated NPM1 transcripts (mutation type A, B, D) in PB post-induction had 
improved outcome if they received alloHCT. This was not observed in 
patients with a reduction exceeding 4-logs (101). Earlier Buccisano et al. 
reported improved outcome for post-consolidation MRD positive 
(determined with MFC-MRD, ≥0.035%) good- and intermediate risk patients 
who received alloHCT as compared to chemotherapy or autoHCT. This was 
not seen for MRD negative patients (102). 
1.6.10 PREEMPTIVE TREATMENT 
For several AML subtypes there has been shown to be a delay between 
molecular relapse, as determined with RT-qPCR, and hematological relapse 
(103-105). This provides a time frame of a few months where preemptive 
therapy could be initiated.  
In a small study by Sockel et al., adult AML patients received azacitidine in 
case of molecular relapse or persistent MRD, defined as an increase or 
persistence in NPM1/ABL1 > 1%, after end of treatment (106). Seven out of 
10 treated patients were still in remission after a median follow-up time of 10 
months, as compared to the previously described median times from 
molecular relapse using RT-qPCR to overt relapse of 2-4 months in NPM1 
mutated AML (25, 61). The prospective RELAZA study investigated the 
effect of azacitidine in AML and MDS patients undergoing alloHCT of 
which the majority had AML. Monitoring was performed regularly after 
alloHCT and patients displaying a minor response (donor chimerism in the 
CD34+ cell fraction <80% but without hematological relapse - i.e. not based 
on MRD) were offered treatment. Some treated patients had continuous 
response without need of further treatment. For patients treated with 
azacitidine who relapsed, the median time to relapse was 231 days from 
donor chimerism levels <80%, which was longer than previous reports (107). 
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In the following RELAZA2 study, adult patients with AML or MDS who 
achieved complete remission were MRD monitored prospectively for 24 
months after end of treatment using quantitative PCR of mutated NPM1 or 
fusion genes CBFB-MYH11, DEK-NUP214, RUNX1-RUNX1T1 (108). 
Again, the proportion of AML patients was approximately 90%. Patients who 
were MRD positive (>1% in PB or BM) in remission received treatment with 
azacitidine. Transplanted patients were monitored with CD34+ donor 
chimerism as described in the RELAZA study. After six cycles of azacitidine 
MRD status was reassessed, and for negative patients the treatment was de-
escalated. Thirty-six percent of treated patients reached MRD negativity. 
Hematological relapse was prevented in 51%. The other 49% relapsed after a 
median of 422 days, which was longer than expected when compared to 
previous results. The OS of the MRD positive patients that responded to 
azacitidine was similar to that of the MRD negative patients. The results 
suggest that preemptive therapy with azacitidine can substantially delay 
hematological relapse in MRD positive AML patients. 
Pozzi et al. assessed WT1 gene expression using RT-qPCR after alloHCT and 
the impact on outcome for patients with AML. They reported that WT1 
expression was the strongest predictor of relapse in multivariate Cox 
regression analysis. Further, patients with MRD positivity (expression levels 
>180 copies/104 ABL1 after alloSCT) in remission were eligible for immune 
intervention either by DLIs or modulation of immunotherapy. Patients that 
had WT1 expression levels >180 copies/104 ABL1 after alloHCT but with 
GvHD, cord blood transplants, early relapse or non-availability of the donor, 
were not eligible for DLI treatment. Comparing the patients with increasing 
WT1 levels who received DLIs and those who did not, the number of relapses 
was comparable, but patients receiving DLIs had a significantly better 5-year 
survival (44% vs 14%). However, whether this was due to a slower disease 
progress of the patients selected for DLI treatment or an actual effect of the 
treatment remains to be proven. They conclude that WT1 expression could be 
used to guide early treatment intervention with immunotherapy (109). 
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1.7 HETEROGENEITY & EVOLUTION OF 
LEUKEMIC CELLS 
 
[…]there is a frequently recurring struggle for existence, it follows that any being, if 
it vary however slightly in any manner profitable to itself, under the complex and 
sometimes varying conditions of life, will have a better chance of surviving, and thus 
be naturally selected. From the strong principle of inheritance, any selected variety 
will tend to propagate its new and modified form. 
 
-Charles Darwin,        
On the origin of species, 1859 
 
1.7.1 IMMUNOPHENOTYPIC SHIFTS IN MFC-MRD 
The sensitivity in predicting relapses with MFC for MRD analysis is rather 
low as 20-40% of MRD negative patients relapse (13, 110-112). This is 
partly explained by immunophenotypic heterogeneity of the leukemic cells. 
Usually only a subpopulation of the leukemic cells has a distinct aberrant 
immunophenotype, required to be displayed on at least 10% of leukemic cells 
to define a LAIP. Further, so called immunophenotypic shifts can be 
observed where the immunophenotype of the leukemic cells alters over the 
course of treatment. Changes in immunophenotype between diagnosis and 
relapse have been described to occur in up to 90% of cases (113-115).  These 
changes may reflect antigenic instability in the original leukemic cells or the 
emergence of a new dominating leukemic clone due to the selective pressure 
of chemotherapy. The current knowledge about changes in 
immunophenotype during treatment and imminent relapse is limited. 
1.7.2 GENETIC HETEROGENEITY OF LEUKEMIC 
CELLS, CLONAL EVOLUTION & CLONAL 
HEMATOPOIESIS 
1.7.3 GENETIC HETEROGENEITY OF LEUKEMIC CELLS 
As previously described, leukemia is derived from a single hematopoietic 
precursor cell that has acquired oncogenic mutations.  In the process of 
leukemogenesis, daughter cells descending from this cell will subsequently 
acquire additional mutations. The cell type with the most malignant 
properties will be selected for and emerge as the dominating clone, although 
subclones in many cases will co-exist. High-throughput genomic analyses 
have based on variant allele frequencies established that AML often is 
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composed of multiple subclones (11, 116) (Figure 7). One of these studies 
reported that more than half of the investigated AML patients had at least one 
subclone in addition to the dominating clone (11). In analogy to the intra-
tumor genetic heterogeneity described for solid tumors, a case study where 
exome sequencing was performed on bone marrow, aspirated from different 
anatomic sites (right and left iliac crest and sternum) in AML-patients, 
revealed differences in subclonal compositions in the different compartments 
(117). The existence of multiple subclones have implications for MRD-
monitoring, and potentially also for treatment as novel targeted therapies are 
introduced. 
 
 
 
 
 
 
Figure 7. Illustration of how the leukemic cells continue to accumulate mutations after the 
leukemia-initiating event (A), giving rise to a dominant clone (C) possessing a growth 
advantage over the other leukemic cells, but also to multiple coexisting leukemic subclones (B, 
D).   
1.7.4 CLONAL EVOLUTION 
This pool of genetically heterogeneous leukemic cells present at diagnosis 
will be exposed to treatment with chemotherapy which exerts a selective 
pressure on the leukemic cells. If the treatment fails to eradicate all leukemic 
cells, some cells with a genotype that renders them more chemotherapy 
resistant might persist and return as the dominant clone at relapse (Figure 8). 
Through this process, mutations that were identified in the pool of leukemic 
cells at diagnosis might not be detectable at relapse. The cytotoxic drugs used 
for treatment are mutagenic and can introduce new mutations in the surviving 
leukemic cells. These mutations can thus be detected at relapse but not at 
diagnosis. In addition, the inherent genetic instability of the leukemic cells 
contributes to acquisition of new mutations. This change in mutational profile 
is called clonal evolution (118). Some mutations, such as in the NPM1 gene, 
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have been demonstrated to be stable during treatment (119, 120). Others, 
such as FLT3-ITDs, tend to change over the course of treatment (119).  
Therefore, recommendations against the use of mutations in FLT3, NRAS, 
KRAS, IDH1, IDH2, MLL-PTD and expression of EVI1 as single MRD 
markers has been given by the ELN MRD Working Party. However, 
mutations in these genes may have prognostic significance in combination 
with other MRD markers (64). On a side note, there also seems to exist a 
tumor heterogeneity at the epigenetic level at diagnosis as well as epiallele 
shifts through progression from diagnosis to relapse (121). 
Figure 8. The leukemic cells at relapse will have some differences in genetic make-up as 
compared to the leukemic cells at diagnosis, i.e. clonal evolution, in part due to the selective 
pressure of chemotherapy as shown here. 
1.7.5 CLONAL HEMATOPOIESIS 
Hematopoietic cell clonality is not a phenomenon only related to AML, but is 
also found in healthy individuals. Two pivotal papers were published 
regarding age-related clonal hematopoiesis in 2014. They showed that 5-10% 
of individuals >70 years had mutations in genes often found mutated in MDS 
and AML (e.g. DNMT3A, TET2, ASXL1) in a substantial proportion of their 
blood cells (122, 123). These individuals had higher risk of developing 
hematological malignancies (MPN, MDS or AML) than individuals without 
age-related clonal hematopoiesis. As the majority of these patients never will 
develop a hematological malignancy, the condition is referred to as clonal 
hematopoiesis of indeterminate potential (CHIP) or sometimes ARCH (age-
related clonal hematopoiesis). Only 0.5-1% of individuals diagnosed with 
CHIP progress to malignant disease (124). This premalignant condition has 
its equivalents in the premalignant conditions of the lymphoid lineage 
(monoclonal gammopathy of undetermined significance (MGUS) and 
monoclonal B-cell lymphocytosis (MBL)). The mutations associated with 
CHIP are mutations that are recurrent also in MDS and AML. Supposedly, 
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HSCs that acquire these mutations will expand as a result of an advantageous 
phenotype and increase the probability of acquisition of additional driver 
mutations. This highlights the stepwise progression from normal 
hematopoiesis to myeloid malignancy (18, 124).  
1.7.6 AML RELAPSE 
Approximately 30-40% of adult AML patients relapse, usually within 2 years 
from diagnosis (125, 126). Relapse is a result of insufficient eradication of 
leukemic cells, clonal evolution of preleukemic cells or a new malignancy 
induced by chemotherapy. The leukemic cells at relapse could therefore 
potentially harbour different mutations than at diagnosis, why new 
morphologic, immunophenotypic and genetic analyses should be performed. 
If the leukemia at relapse lacks resemblance of the leukemia at diagnosis, the 
possibility of a new treatment-related malignancy should be considered, 
especially for late relapses.  
The prognosis after relapse is poor, with reported 3-year OS for adult AML 
patients of 24% (APL included) (127) and 1-year survival of 19-23% for 
patients with relapse after alloHCT (126, 128). The chance of cure is 
dependent on age, cytogenetic risk, duration of first remission and treatment 
with alloHCT in second remission (CR2).  For patients eligible for alloHCT, 
the transplantation is performed as soon as possible after CR2 is reached, as it 
usually is shorter than the first remission (CR1). Although the relapse rate is 
equivalent in children, the outcome after relapse is better than for adults with 
reported total 5-year OS of 39% and 5-year OS of 61% for allografted 
patients (129). Hematological relapse is defined as presence of ≥ 5% 
leukemic cells in BM assessed by morphology or MFC or reappearance of 
blasts in blood (47). Monitoring of patients after end of treatment with RT-
qPCR enables earlier detection of relapse, so called molecular relapse. 
Molecular relapse has for RT-qPCR been defined as an increase of MRD ≥ 
1log10 between two consecutive samples in a patient with previous molecular 
remission (64). Molecular relapse is associated with a very high risk of 
hematological relapse (104, 105, 130). This information enables the 
possibility of preemptive intervention. 
One aspect which needs to be considered when using MRD for monitoring 
after end of treatment is the relapse kinetics of the disease. Different subtypes 
of AML (i.e. with different genetic aberrations) have been shown to differ in 
progression time from molecular to hematological relapse. The reported time 
from molecular relapse in BM to haematological relapse for patients with 
inv(16) was 6 months; NPM1/FLT3-ITD- 4 months; NPM1/FLT3-ITD+ 2 
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months and one month for patients with KMT2A-rearrangements (131). For 
patients with RUNX1-RUNX1T1, the reported time from molecular relapse in 
BM and PB to haematological relapse was 0.8 months and 1.6 months 
respectively (92). These differences could have implications for testing 
intervals as well as choice of preemptive treatment. The optimal testing 
intervals remain to be determined. The ELN MRD Working Party 
recommends monitoring of molecular MRD markers NPM1, RUNX1-
RUNX1T1, CBFB-MYH11 and PML-RARA every 3 months for 24 months 
after end of treatment (64). 
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2 AIM 
The overall aim of this thesis has been to improve the treatment follow-up of 
patients with AML by analysis of MRD and, thus, to provide better support 
for treatment decisions and chance of improved survival. 
 
2.1 SPECIFIC AIMS 
• To develop and validate a next generation sequencing based method 
for MRD analysis in AML (Paper I and Paper II) 
• To evaluate if MRD analyzed by deep sequencing predicts the 
outcome for patients with NPM1 mutated AML undergoing alloHCT 
(Paper III) 
• To assess the ability of patient-tailored deep sequencing MRD 
analysis of blood to detect a pending relapse in patients that have 
completed their AML treatment (Paper IV) 
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3 METHODOLOGICAL CONSIDERATIONS 
This section provides an overview of the samples and methods used for the 
studies. Detailed descriptions are found in the Method sections of attached 
papers. 
3.1 PATIENT SAMPLES 
3.1.1 PAPERS I & II 
Bone marrow cells or peripheral blood from adults (Paper I) and children 
(Papers I & II) with AML were collected at diagnosis and during follow-up 
based on availability after complete diagnostic work-up at the Department of 
Clinical Chemistry, Sahlgrenska University Hospital. The pediatric patients 
were treated according to the NOPHO-DBH AML-2012 protocol. Patients 
with AML associated with trisomy 21, APL (t(15;17)(q22;q21); PML-
RARA), juvenile myelomonocytic leukemia, AML secondary to bone marrow 
failure syndromes and treatment-related AML were excluded. The studies 
were performed according to the Declaration of Helsinki and approved by the 
Regional Ethical Review Board in Gothenburg. Informed consent was 
obtained from guardians and when age appropriate from the patients. 
3.1.2 PAPER III 
Bone marrow aspirate slides from adult patients with AML were retrieved 
from biobanks at Sahlgrenska University Hospital, Gothenburg and Skåne 
University hospital, Lund. Included patients had undergone alloHCT between 
2005 and 2015 and had identified mutation in the NPM1 gene at diagnosis. 
Patients had consented to biobanking for research purposes and the study was 
approved by the Regional Ethical Review Board in Gothenburg. 
3.1.3 PAPER IV 
Bone marrow or peripheral blood samples from children were collected at 
diagnosis and relapse. Blood samples were collected monthly after 
completion of therapy until relapse or end of follow-up (minimum 1 year 
from inclusion or 1.5 years after end of treatment). Samples were biobanked 
at Aarhus University Hospital for patients from Denmark, Finland and 
Norway, and at Sahlgrenska University Hospital for Swedish patients. All 
pediatric patients (0-17 years) treated on the NOPHO-DBH AML-2012 
protocol that achieved CR after first line of therapy/alloHCT were eligible for 
enrollment. Only relapsed patients were included. Exclusion criteria for the 
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NOPHO-DBH AML-2012 protocol are stated in section 3.1.1. Written 
informed consent was obtained from guardians or when age appropriate from 
patients. The study was performed according to the declaration of Helsinki 
and approved by local or national ethics review boards in Denmark, Norway, 
Finland and Sweden.  
3.2 FLUORESCENCE ACTIVATED CELL 
SORTING (FACS) 
The use of cell sorting by FACS allows simultaneous enrichment of several 
cell populations from a single sample. The use of multiple antibodies in 
combination with analysis of cell size (forward scatter-FSC) and complexity 
(side scatter-SSC) enables good characterization of the target cells. This is in 
opposition to alternative methods such as enrichment with magnetic-activated 
cell sorting (MACS). 
FACS was used for sorting of leukemic cells and lymphocytes (Paper I, II & 
IV) as part of the process to characterize the leukemic cells with regard to 
mutations. The rationale was to obtain the best estimation possible of the 
leukemic cell variant allele frequency (VAF), to assess which mutations were 
likely to be present in the majority of leukemic cells at diagnosis and 
therefore suitable MRD markers. The main sorting strategy was hence to use 
immunophenotypic markers which separated the leukemic cells from other 
hematopoietic cells, without obvious exclusion of any leukemic cells. As all 
AML samples are extensively analyzed with flow cytometry at diagnosis in 
clinical routine, the sorting strategy of viably frozen leukemic cells was 
possible to establish in advance. The samples were prepared using bulk lysis, 
followed by washing and staining. For the great majority of cases, the core 
blast identification markers CD45, CD117, CD34 and HLA-DR were used to 
identify leukemic populations (13). Lymphocytes were sorted based on their 
SSC properties and CD45 expression. An example of the gating strategy is 
illustrated in Figure 9. Satisfactory levels of purity at around 95% were 
reached for most cases.  
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Figure 9. Illustration of the gating strategy used for FACS-sorting of leukemic cells and 
lymphocytes, selecting viable cells and singlets based on SSC and FSC properties, following 
gating of the SSClow,CD45+H, CD34- and CD117- lymphocytes and the SSClow, CD45+D, 
CD34+ and CD117+ leukemic cells (in this particular case). 
3.3 NEXT GENERATION SEQUENCING 
The dominating NGS method for the time being is the sequencing by 
synthesis (SBS) approach. In the preparation step, the DNA intended for 
sequencing is flanked with adaptor oligonucleotides. The end part of these 
oligonucleotides is complementary to clonally amplified oligonucleotides 
that are fixed to the flow cell glass. Each single-stranded DNA added binds to 
the flow cell and give rise to a cluster of identical strands through a bridge-
amplification process (cluster generation). The adaptor sequence also 
contains a primer-binding site where the sequencing primer will bind. During 
sequencing, nucleotides are added in a cyclic manner and when the correct 
nucleotide is incorporated in the growing DNA strand, a fluorescent signal 
specific for the nucleotide is emitted and recorded. All signals from a given 
cluster are recorded together and millions of clusters are analyzed 
simultaneously. The sequencing is then repeated for the reverse strand after a 
DNA replication process. After the sequencing process is completed, the 
output sequencing data is aligned to the human reference genome and 
analyzed.  
One application of NGS is to interrogate shorter genomic regions at very high 
resolution - targeted deep sequencing. Since leukemic cells have acquired 
mutations that do not exist in the healthy cells, these mutations can be used as 
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MRD markers (similarly as for RT-qPCR). In contrast to RT-qPCR, genomic 
DNA (gDNA) instead of mRNA is quantified which is directly correlated to 
the number of leukemic cells. Targeted deep sequencing as method for MRD 
analysis has been described in AML for recurrent mutations, either selected 
genes or gene panels, with varying applicability and sensitivity (7, 132-138). 
The use of exome sequencing and/or whole genome sequencing has also been 
described for identification of leukemia-specific mutations followed by 
targeted deep sequencing MRD analysis (and has been our approach in some 
of the studies included in this thesis) (139-141).   
3.3.1 EXOME SEQUENCING 
In order to screen the genome of leukemic cells for mutations, two main NGS 
based options exist; whole genome sequencing (WGS) and whole exome 
sequencing (WES). In WGS, the entire genome is sequenced (exons, introns 
and intergenic regions) whereas in WES only the exons, which constitute a 
fraction of the entire genome, are sequenced. One advantage of WGS over 
WES is that it would enable detection of more mutations, with the possibility 
of identifying more MRD suitable mutations per case. Furthermore, the data 
should be more unbiased as oligonucleotide probes are used to hybridize to 
target regions in the genome in WES library preparation. The rationale for 
choosing WES over WGS in these studies was that protein-coding mutations, 
with potential leukemogenic properties were of most interest (for potential 
exploration in further studies).  Further reasons were the local availability, 
lower cost, easier data storage and that the bioinformatics analysis of WES 
data was more established at study initiation.  
To identify leukemia-specific mutations, exome sequencing was performed 
on DNA extracted from sorted leukemic cells and lymphocytes respectively 
(Paper I, II and IV). The Illumina platform was used 
(HiScanSQ/NextSeq500) using paired-end reads (2x75bp). Post-sequencing, 
reads were aligned to the human reference genome (build hg19, UCSC) using 
Burrows-Wheeler aligner (BWA) (142). For variant calling of SNVs, the 
software Mutect was used and small insertions/deletions were identified 
using Strelka and VarScan2 (143-145). 
3.3.2 CHOOSING MUTATIONS SUITABLE FOR MRD-
ANALYSIS 
In papers I, II and IV, we used FACS to sort leukemic cells and lymphocytes 
with the purpose of identifying mutations suitable as MRD markers using 
exome sequencing. Through this process we could identify leukemia-specific 
mutations, both potential driver mutations and passenger mutations. 
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Heterozygous mutations in a sorted cell population have a 50% VAF. A 
fraction of the mutations identified as leukemia-specific with exome 
sequencing have VAFs<50%, suggesting subclonality for these mutations 
(Figure 10A). In order to only identify heterozygous mutations present in the 
majority of the leukemic cells, a 95% confidence interval (CI) for the true 
VAF was calculated for each identified mutation based on the observed VAF 
and the sequencing depth in each specific position. Mutations with an upper 
CI below 0.5 were considered potentially subclonal and thus primarily not 
suitable as MRD markers (Figure 10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Leukemia-specific mutations identified in two cases of AML in paper I, where 
groups of mutations cluster at low frequency, suggesting subclonality (A, red boxes). 
Mutations not likely to be present in all leukemic cells, based on an upper 95% CI level for the 
true VAF below 50%, were not primarily used as MRD markers (B, mutations with 95% CI 
below 50% shown in red).  
 
B) 
A) 
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3.3.3 TARGETED DEEP SEQUENCING 
In order to estimate the frequencies of MRD suitable mutations with high 
sensitivity in follow-up samples, an amplicon based sequencing strategy was 
chosen. There are other methods that could have been used for this intent, 
such as qPCR or ddPCR. However, both these methods require custom 
design of not only primers but also probes, which would make patient-
tailored analyses more laborsome. As outlined in paper III, targeted deep 
sequencing also permits analysis of unknown mutations in a given genomic 
region.  
PCR primers were designed for the Illumina Truseq-library preparation 
system. Amplicons were designed to span 50-120 nucleotides 5’- and 3’- of 
the leukemia-specific mutation of interest. PCR products were purified using 
Agencourt® AMPure® XP beads (Beckman Coulter, Brea, CA) to remove 
residual primer and sequenced in multiplex with dual unique indexing on the 
MiSeq platform (Illumina, San Diego, CA) and using paired-end reads 
(2x150bp). The PhiX bacteriophage genome was added for increased library 
diversity. To achieve a high sequencing depth, only eight to ten samples were 
analyzed per run. No mismatches were allowed for demultiplexing, as 
compared to one mismatch allowed by default. Acquired reads were stitched 
using PEAR with default parameters and quality filtered using the FASTX-
Toolkit (146). Alignment to the human reference genome was performed 
with the Burrows-Wheeler aligner (BWA) (142). Only reads with a perfect 
match of nucleotides flanking the mutation site was kept for analysis. The 
VAF was defined as (mutated reads/(wildtype reads + mutated reads)). The 
sequencing process is associated with some degree of base-calling errors and 
sequence specific errors, where GGC motifs are more affected (147, 148). To 
correct for position-specific errors to obtain error corrected VAF (VAFEC), 
we used reference samples for each analyzed position in Papers II and IV. A 
flow chart for the targeted deep sequencing process is showed in Figure 11. 
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Figure 11. Illustrated is the work flow of targeted deep sequencing, from adapter ligation 
using custom made primers for the mutation region to mutation detection in aligned reads and 
estimation of VAFEC.  
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3.4 SANGER SEQUENCING 
Sanger sequencing was used to validate the performance of exome 
sequencing and the succeeding bioinformatics analyses for identification of 
leukemia-specific mutations in Paper I. As all tested mutations were validated 
and the same workflow was used in Papers II and IV, additional testing was 
considered redundant. DNA from diagnostic bone marrow cells was 
sequenced on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, 
Carlsbad, CA) using PCR primers specific for the mutation sites and BigDye 
Terminator v.1.1. 
3.5 MOLECULAR CHIMERISM 
Patients undergoing alloHCT are routinely monitored for engraftment 
efficacy after transplant using donor chimerism analysis. In this analysis the 
percentage of donor cells is estimated using PCR of short tandem repeat 
sequences or fluorescence in situ hybridization (FISH) of sex chromosomes, 
applicable in cases of gender mismatch transplantation. The method is less 
sensitive than targeted assays since it is not specific for leukemic cells and 
thus not a method for MRD analysis. However, there is a known association 
between increased amount of recipient cells (mixed chimerism) and relapse 
(149, 150).  
In Paper III, patients with AML with mutation in NPM1 were investigated 
regarding the association between targeted deep sequencing MRD positivity 
around the time of transplantation and outcome. As clinical data from bone 
marrow chimerism analyses was available for a fraction of the included 
cases, the results were compared to deep sequencing analysis.  
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4 RESULTS 
4.1 PATIENT-TAILORED ANALYSIS OF 
MINIMAL RESIDUAL DISEASE IN ACUTE 
MYELOID LEUKEMIA USING NEXT 
GENERATION SEQUENCING (PAPER I) 
One of the most important risk stratifying factors in AML is response to 
treatment, which is determined by analysis of MRD. The most established 
method for MRD analysis is MFC-MRD, which is applicable for the majority 
of AML patients but is also associated with several limitations. These 
limitations include difficulties in identifying immunophenotypes specific for 
the leukemic cells – LAIPs. Further, cells with the identified LAIPs often 
only represent a fraction of the leukemic cells, which hampers the sensitivity 
of the method. Higher sensitivity is acquired with RT-qPCR analysis of 
recurrent genetic aberrations, but the analysis is reserved for the minority of 
AML patients with recurrent chromosomal translocations or mutations. 
We therefore decided to develop a complementary method using targeted 
deep sequencing. To identify MRD suitable target mutations highly specific 
for the leukemic cells, but also present in the majority leukemic cells of the 
individual patient, leukemic and normal cells (lymphocytes) from 17 patients 
were sorted from diagnostic samples using FACS. DNA from respective cell 
type was exome sequenced after which bioinformatic as well as statistical 
analyses were performed. In this manner we identified MRD suitable 
mutations at diagnosis for all but one patient. A total of 262 leukemia-
specific mutations were identified in the 17 analyzed cases using exome 
sequencing, of which 191 were considered MRD-suitable (median 11, range 
0-25, per case). There was a correlation between mutation burden and age (rs 
= 0.76, p<0.001) and the number of mutations was significantly lower in 
children (median 6, range 0-10) than in adults (median 18.5, range 12-34). 
The most common mutation class was SNVs, with transitions occurring more 
frequently than transversions. We also compared the results from exome 
sequencing to results from conventional genetic analyses used in routine 
diagnostics. Mutations in NPM1, FLT3-ITDs, numerical and most structural 
chromosomal aberrations were identified, but not balanced translocations. 
Deep sequencing amplicon libraries were created using primers specific for 
the target region and sequenced at high depth on the Illumina Miseq platform.  
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Dilution series of leukemic DNA, containing three leukemia specific SNVs 
in different genes and a 4 base pair (bp) insertion in the NPM1 gene, 
demonstrated linearity down to 0.025% for SNVs and 0.017% for the 4 bp 
insertion. Limits of detection were established at 0.025% for SNVs and 
0.007% for the insertion based on the obtained VAF in normal samples 
(mean+3SD). As proof of principle, bone marrow samples from a patient 
with AML under treatment were analyzed for MRD with targeted deep 
sequencing. There were high and significant correlations between the 
detected mutation load of the three SNVs and the NPM1 insertion. The 
mutation load for the NPM1 insertion was confirmed using qPCR of DNA, 
showing good correlation between results from deep sequencing and qPCR.  
Limitations of this study included the fact that the study cohort was small and 
not population based and the identified mutations might therefore not be fully 
representative for AML. Further, only mutations from one patient were 
analyzed with targeted deep sequencing. 
In conclusion, we showed that exome sequencing of DNA from cells sorted 
with high purity at diagnosis can identify leukemia-specific mutations that 
may be used for MRD analysis in a personalized manner in both adult and 
childhood AML. We also demonstrated the potential of targeted deep 
sequencing as a sensitive method for analysis of small amount of residual 
leukemic cells.  
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4.2 ACCURATE AND SENSITIVE ANALYSIS OF 
MINIMAL RESIDUAL DISEASE IN ACUTE 
MYELOID LEUKEMIA USING DEEP 
SEQUENCING OF SINGLE NUCLEOTIDE 
VARIATIONS (PAPER II)  
Molecular MRD analysis is today only available for the minority of AML 
patient with recurrent cytogenetic aberrations or mutations. To address this 
limitation, we developed patient-tailored targeted deep sequencing. This 
method enables the use of also non-recurrent leukemia-specific somatic 
mutations as markers for MRD, which could extend the applicability of 
molecular MRD analysis to a larger number of patients.  
In this study we validated the patient-tailored targeted deep sequencing 
method for MRD analysis described in paper I. The same method was used as 
in paper I, but with some elaborations. To correct for sequencing errors and 
hence achieve a better determination of the true VAF, we corrected each 
result for the background signal in the specific position. This was performed 
by determining the VAF of the position of interest in a reference sample from 
a healthy individual. The resulting position-specific error corrected value was 
denoted VAFEC.  
This correction reduced the noise level and was shown to be important at 
lower VAF levels due to larger relative differences between VAF and 
VAFEC. For estimation of the limit of detection (LOD), normal samples were 
analyzed for 15 different SNVs. The LOD was dependent on the sequencing 
depth and estimated to VAFEC 0.02% at a sequencing depth of 5 x 105 reads, 
with only minor decrease in LOD at higher depths. To determine linearity, a 
commercially available DNA reference standard containing five different 
SNVs and one deletion at 1% VAF was used.  Dilution series were performed 
in triplicate in the low VAF range (0.008-1%) followed by targeted deep 
sequencing on the Illumina MiSeq platform as previously described. 
Linearity was seen down to levels of approximately VAFEC 0.03%. Between 
run variations (CVs) were estimated for SNVs at different variant allele 
frequency levels. At VAF 1% the CV ranged between 2.2%-5.7% and for 
samples diluted to VAF 0.1% between 8.8-19.4%.  A low relative bias of 
7.9% (2.5%-15.3%) was seen at VAF 1%. To test the method during 
treatment follow-up, biobanked bone marrow samples from six children with 
AML were analyzed using targeted deep sequencing at different time points 
during treatment. Two to three mutations per patient were used as MRD-
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markers, determined MRD suitable using our filtering system described in 
paper I. The results from deep sequencing were compared to MRD analysis 
using MFC-MRD and showed high concordance and superior sensitivity. 
Two patients, who later relapsed, were MRD positive with deep sequencing 
and MRD negative with MFC-MRD after end of induction therapy, the risk 
stratifying time point in the protocol. Two patients, who remained in 
remission, were MRD negative with both methods after end of induction 
therapy. Regarding the two additional patients, one lacked data from MFC-
MRD for comparison and the final patient was treated off-protocol. Overall, 
none of the patients were at any time determined MRD positive with MFC-
MRD and MRD negative with deep sequencing. Further, there was a high 
concordance with fusion gene expression RUNX1-RUNX1T1 and KMT2A-
MLLT10 using RT-qPCR. All mutations present in bone marrow at VAF 
>0.1% were detected also in peripheral blood, which is of importance for 
applicability of the method for MRD-surveillance in blood.  
The limitations associated with this study were that not all possible SNVs 
were included in the study of accuracy, precision and limit of detection. 
Further the low number of included patients only allowed for descriptive 
study on leukemia kinetics using different methods for MRD analyses and no 
conclusive results on the predictive value of deep sequencing. 
In conclusion, we showed that patient-tailored targeted deep sequencing of 
SNVs, present in virtually all cases of AML, enables reliable and sensitive 
MRD analysis. Good accuracy, precision and linearity were seen at low VAF 
range. We reported concordance of results from targeted deep sequencing 
with MFC-MRD and RT-qPCR with a suggested superior sensitivity over 
MFC.  
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4.3 MINIMAL RESIDUAL DISEASE ASSESSED 
WITH DEEP SEQUENCING PREDICTS 
RELAPSE AFTER ALLOGENEIC STEM 
CELL TRANSPLANT IN AML (PAPER III) 
In addition to evaluating early response to treatment, MRD measurements 
could be used in patients undergoing alloHCT for risk stratification and 
subsequent adjustment of immunomodulatory treatment (immunomodulatory 
drugs or DLIs). Mutations in the NPM1 gene are recurrent in AML, present 
in approximately 30 % of adult AML cases (151). The reported stability of 
mutations in the NPM1 gene over the course of treatment makes these 
mutations suitable as MRD markers (43, 152-154). RT-qPCR has been 
established as a predictive tool by several groups for MRD analysis in AML 
with mutation in the NPM1 gene following alloHCT (97, 98). However, to 
detect the numerous different recurrent mutations in the NPM1 gene, a large 
number of specific RT-qPCR assays would be required. Using targeted deep 
sequencing, the same assay could be applied for all recurrent insertions in 
exon 12 of NPM1, and serve as a cost-effective alternative for MRD analysis. 
Here we evaluated the predictive value of this method. 
Twenty-nine patients in morphological remission at the time of alloHCT 
were assessed for the prognostic impact of NPM1 MRD status on relapse-free 
survival (RFS) and overall survival. Samples from within one month before 
alloHCT were available for 25 patients and from three months after alloHCT 
for 27 patients. Targeted deep sequencing was performed as described in 
paper I (140). A cutoff value of VAF 0.02% for MRD positivity was used 
based on previously shown linearity of the assay down to this level. The 
study outline is illustrated in the figure 12.  
Two out of 3 pre-transplant MRD positive patients relapsed, as compared to 
4 out of 22 MRD negative patients. Post-transplant, 4 out of 5 MRD positive 
patients and 3 out of 22 MRD negative patients relapsed. MRD status 
revealed significant associations with clinical outcome: 3-year RFS 20% for 
MRD positive vs 85% for MRD negative (p<0.001) and OS similarly 20% vs 
89% (p<0.001) respectively. Post-transplant deep sequencing MRD predicted 
both RFS (HR 45, 95% CI 2-1260, p = 0.025) and OS (HR 49, 95% CI 2-
1253, p = 0.019). This was independent of other known risk factors including 
age, disease status at transplant, conditioning intensity, cytogenetic risk 
stratification and FLT3-ITD status. The result from bone marrow chimerism 
analysis that was performed as part of clinical routine approximately 3 
months post-transplant was compared to results from NPM1 MRD analysis. 
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Of the five post-transplant MRD positive patients, only one displayed mixed 
T cell chimerism. No significant association was found between T cell 
chimerism status and outcome. 
Limitations of the study included that it was retrospective, that the study 
cohort was relatively small and involved limited comparisons to other 
methods.  
In summary, we reported deep sequencing of NPM1 to be an applicable and 
predictive tool for MRD assessment after alloHCT in AML, confirming 
previous reports on MRD analysis using RT-qPCR. The possibility to predict 
risk of relapse in patients undergoing alloHCT using MRD analysis by 
targeted deep sequencing of NPM1 would provide a better decision support 
for treatment and thus the chance of improved survival.  
 
 
   Figure 12. Visual abstract of Paper III.  
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4.4 PATIENT-TAILORED DEEP SEQUENCING 
OF BLOOD ENABLES EARLY DETECTION 
OF RELAPSE IN CHILDHOOD ACUTE 
MYELOID LEUKEMIA (PAPER IV) 
Despite the fact that the majority of children with AML reach complete 
remission, 30-40% will eventually relapse (155, 156). After relapse the 
prognosis is dismal with a 5-year OS of 40%, even with intense treatment 
(129). For adult AML, a recent study has shown that detection of molecular 
relapse enables preemptive treatment with azacitidine that prolong the time 
to, or even prevent, hematological relapse (108). For transplanted patients, 
preemptive interventions upon molecular relapse using DLIs and modulation 
of immunosuppression have been described (157-159). Here we applied our 
patient-tailored deep sequencing MRD strategy to analyze blood samples 
preceding relapse to determine the applicability for early detection of relapse 
and to study relapse kinetics. 
Children treated with the NOPHO-DBH AML-2012 protocol since 2016 
were offered participation in the “Early detection of relapse study”. Blood 
samples were prospectively collected monthly after end of treatment and 
biobanked. Children with relapse during the sampling period were included 
in this study. At the time of writing this thesis, nine childhood AML patients 
have been included (of a total expected number of approximately 20 included 
patients).  
In total, 53 leukemia-specific mutations were identified at diagnosis (median 
4, range 2-12 per patient), of which 33 were present also at relapse (median 2, 
range 1-9 per patient). Fewer than half of the genes identified to be mutated 
at diagnosis were reported in the COSMIC database to be recurrently mutated 
genes. Mutations that fulfilled our previously established criteria for being 
suitable as MRD markers were identified in 7/9 cases. A median of 2 (range 
1-3) leukemia-specific SNVs were quantified per patient with deep 
sequencing in the PB samples preceding relapse. In 8/9 cases, leukemia-
specific mutations were detected in blood before hematological relapse, and 
the first sample displaying MRD positivity was collected at a median of 90 
days (range 0-241 days) before relapse. The relapse kinetics varied between 
individuals and AML subtypes. For patients not receiving preemptive 
therapy, the median doubling time of the mutation burden was 7 days (range 
4-28 days) and for patients receiving preemptive treatment 25 days (14-26 
days). We explored a potential definition of molecular relapse as a doubling 
of VAFEC between two MRD positive samples in a patient who previously 
Next Generation Sequencing for Measurable Residual Disease Detection in Acute Myeloid Leukemia 
52 
tested negative. This occurred in 6/9 patients at a median time of 80 days 
(range 25-227 days) before relapse and for 2 additional patients VAFEC 
doubling coincided with overt relapse. The ELN recommended definition of 
molecular relapse, one log10 increase between two positive samples in a 
patient who previously tested negative, occurred only in 3/9 patients. For two 
of these three patients, the one log10 increase coincided with overt relapse. 
Thus, VAFEC doubling could be a better definition of molecular relapse when 
analyzing mutation burden than the one log10 increase commonly used for 
transcripts. 
The limitations of this study include that no comparisons to other methods for 
MRD analysis was performed and that only relapsed patients were analyzed. 
The low number of patients included so far limits the possibility to compare 
the relapse kinetics of different AML subtypes. 
In conclusion, the results showed that patient-tailored deep sequencing 
enables early detection of relapse, permitting molecular monitoring after end 
of treatment with the potential to guide preemptive treatment.  
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5 DISCUSSION 
This thesis aimed at improving the treatment follow-up for patients with 
AML by investigating the potential of targeted deep sequencing for analysis 
of MRD. We report that MRD-suitable SNVs can be identified with exome 
sequencing at diagnosis for the majority of patients and that these mutations 
can be reliably monitored with high sensitivity during follow-up with 
targeted deep sequencing. The degree of sensitivity fulfills the ELN 
consensus specification for molecular MRD analyses of detection down to 
0.1% leukemic cells. Targeted deep sequencing allows for analysis of 
residual leukemia during treatment (Paper I & Paper II), around the time of 
alloHCT (Paper III) and for monitoring of blood after end of treatment for 
early detection of imminent relapse (Paper IV). 
5.1 CHALLENGES OF MRD TESTING IN AML 
Although abundant literature shows superior outcome for MRD negative over 
MRD positive patients, a major limitation at the moment is the lack of large 
prospective randomized trials showing that relapse risk can be reduced in 
MRD positive patients with treatment intervention (160). There is also a vast 
variation in study design concerning methodology, cutoff for MRD 
positivity, testing time points and sample types.  
Many studies have used specific landmark time points during or after 
treatment. Instead of using absolute levels in some studies exploring RT-
qPCR, the relative differences between measurements have been used for risk 
stratification (161-163). The time points that are most discriminatory in 
outcome and most useful in clinical practice remain to be determined for 
different subtypes of AML and methods used. Conceivably, the later the time 
point displaying MRD positivity during treatment, the stronger predictor of 
adverse outcome (due to chemotherapy resistance of leukemic cells). 
However, risk stratification at early time points yields more auxiliary time for 
treatment planning. Perea et al. reported a higher cumulative incidence of 
relapse (CIR) for MFC-MRD positive (≥0.1%) and a lower CIR for MFC-
MRD negative adult AML patients after end of treatment as compared to 
earlier time points during treatment (164). Tierens et al. showed that MFC-
MRD positivity (≥0.1%) before consolidation treatment had higher 
association to adverse outcome than MRD positivity after first induction in 
childhood AML (60). The instruction in the current Swedish protocols (both 
for adults and children) is to use MFC-MRD after two courses of 
chemotherapy, with 0.1% leukemic cells as cutoff.  
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Bone marrow is the most commonly used material for MRD analysis. A 
correlation between levels in BM and PB has been shown with different 
methods (MFC, RT-qPCR & targeted deep sequencing), but generally with 
multifold lower MRD levels in PB (141, 165-167). Krönke et al. analyzed 
paired BM and PB samples with RT-qPCR of NPM1 and reported discrepant 
results during the induction and consolidation period (46% of PB negative 
samples showed positivity in BM) (167). After treatment this number 
decreased to 18%. The results from this study suggest a higher sensitivity of 
BM at early time points.  Some studies have reported that presence of MRD 
during treatment using RT-qPCR PB is equally (CBF-AML) or more (NPM1) 
discriminatory of outcome than in BM (91, 161). RT-qPCR MRD analysis of 
RUNX1-RUNX1T1 in BM after end of treatment has been shown more 
sensitive over analysis of PB, but only PB was predictive of relapse (168). 
Another study investigating adult AML patients with RUNX1-RUNX1T1 
reported that an achievement of a 2.5 log10 reduction in fusion transcript 
levels after course 1 in both BM and PB was associated with a lower risk of 
relapse (92). Lower risk of relapse was also seen for patients achieving a 3 
log10 reduction after course 2. After end of treatment, MRD negativity in both 
BM and PB was an independent favorable predictive marker for relapse risk 
and OS. In the monitoring situation, the use of blood instead of bone marrow 
is associated with several practical advantages, especially in childhood AML 
where general anesthesia is needed for bone marrow aspiration. The potential 
usefulness of PB over BM at different time points using different methods 
needs to be further clarified. 
No method used for analysis of MRD has perfect sensitivity and specificity. 
Regardless of method used, a proportion of MRD negative patients seems to 
relapse. There are several possible reasons for this. a) There could be residual 
leukemic cells below the detection limit of the MRD assay used. b) The 
leukemic cells might lose the MRD markers during the course of treatment 
through immunophenotypic shift or clonal evolution. c) The sample could be 
unrepresentative, where non-homogenous distribution of the leukemic cells in 
bone marrow or blood, hemodilution or scarce sample material could render a 
false negative result (117, 169). Not all MRD positive patients are bound to 
relapse regardless of method. It is known that some leukemia-specific fusion 
transcripts can be detected in the bone marrow of patients remaining in long-
term remission (170-172). Possible explanations include that the immune 
system can hold the low number of leukemic cells at bay or that the target 
cells are in fact not cells with inherent potential to cause relapse (e.g. 
preleukemic mutations). The inter- and intraindividual genetic and 
immunophenotypic diversity of AML necessitates individualized MRD 
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testing, where clinically relevant time points of testing, sample types and 
thresholds for MRD positivity have to be identified for each individual assay. 
5.2 WHAT ARE WE MEASURING? 
The aim of any MRD analysis in AML is to adequately determine the number 
of persisting cells with the potential to cause relapse. It is thus important to 
keep in mind what we are measuring using different methods for MRD 
analysis (i.e. target deep sequencing, RT-qPCR and MFC-MRD).  
In targeted deep sequencing, leukemia-specific mutations are quantified at 
the gene level – DNA level. Since each cell contains two copies of each gene 
(alleles), and the mutations in most instances occur in one of these alleles 
(heterozygous mutations), the ratio is exactly 1:2 between the number of 
mutations and originating cells. In RT-qPCR, the number of transcripts 
originating from the leukemia-specific genetic aberration is analyzed – 
mRNA level. Here, there is no exact relationship between the sample target 
gene mRNA expression and the number of originating cells, as the gene 
expression at the cell level can vary greatly. This means that the level of 
detection varies between different RT-qPCR assays, but also that the window 
of detection is generally broader than for MRD analyses at the DNA level. In 
MFC each cell is analyzed for presence, absence or aberrant expression of 
cell-surface or cytoplasmatic antigens. Thus, the markers analyzed are not 
directly reflecting the leukemogenic genetic lesions. Clearly abnormal 
immunophenotypes can be used for MRD analysis, but are usually not 
present on all cells suspected to be leukemic. Further it can be difficult to 
distinctly separate the leukemic cells from normal cells in a regenerating 
bone marrow.  
The fact that different methods to measure MRD have different biological 
molecules as their targets and are associated with different technical 
difficulties entails that different results could be obtained from measurements 
of the same samples. The interpretation of discordant results can be 
challenging.  In paper II we compared MRD assignments from targeted deep 
sequencing with those obtained from MFC-MRD. Concordant results were 
seen for 18/27 investigated samples. Nine samples were determined MRD 
positive with deep sequencing and MRD negative with MFC. No samples 
determined negative with targeted deep sequencing were determined positive 
with MFC, suggesting a lower sensitivity of MFC. Higher concordance was 
seen between deep sequencing and RT-qPCR of fusion transcripts RUNX1-
RUNX1T1 and KMT2A-MLLT10, where 13/14 samples had concordant MRD 
assignments (8 MRD positive and 5 MRD negative with both methods). Other 
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studies have described low concordance rates when comparing MRD 
measurements obtained from MFC and RT-qPCR after induction. Inaba et al. 
studied MRD response after induction in childhood AML and showed that 
86% of samples determined MRD positive with RT-qPCR were determined 
MRD negative with MFC. Similarly to what we showed for deep sequencing 
in paper II, they also describe that almost all samples (99%) determined to be 
MRD negative with RT-qPCR were also MRD negative by MFC (82). No 
additional predictive value of RT-qPCR to MFC-MRD was seen. However, 
only a few patients monitored with RT-qPCR relapsed. In a study from our 
research group, Karlsson et al. demonstrated slower response kinetics during 
treatment in childhood AML when MRD was assessed at day 15 after 
induction and before consolidation with RT-qPCR of CBF-AML and 
KMT2A-rearrangements, than for MRD assessed by MFC analysis. They 
further showed that this could be explained by the presence of fusion 
transcripts in cells with mature immunophenotypes, i.e. cells that are not 
defined as MRD in the MFC analysis (173). The presence of AML associated 
fusion transcripts in a mature cell strongly implies leukemic descendance. 
However, as previously described in Challenges of MRD testing in AML, it is 
not always clear which leukemic cells that have the inherent potential to 
cause relapse. The differentiated cells harboring leukemic fusion transcripts 
probably constitute of cells without leukemogenic potential. An alternative 
explanation to obtaining a relatively higher MRD result from molecular 
MRD analysis in comparison to the number of immature cells in the sample, 
would be that the target gene is expressed in preleukemic cells lacking 
additional mutations contributing to leukemic transformation. The persistence 
of some fusion transcripts in long-term remission has been described (82, 
170-172), but also for leukemia associated somatic mutations, which is 
further elaborated in the section below. 
5.3 IDENTIFYING MRD SUITABLE SOMATIC 
MUTATIONS 
To make a well-grounded assessment of the MRD-suitability of identified 
mutations in the clinical setting, i.e. mutations specific to leukemic cells with 
presence in the majority of leukemic cells, an adequate estimate of leukemic 
cell count is needed. This is necessary in order to identify mutations present 
in the all leukemic cells, including the dominating clone and potential 
subclones, see Figure 7. In papers I, II and IV, we have used FACS sorting to 
enrich the leukemic cell population and normal lymphocytes before exome 
sequencing.  In paper I, we showed that this procedure could be used to 
identify leukemia-specific mutations, present in the majority of leukemic 
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cells and hence suitable as MRD markers, already at diagnosis. The exclusion 
of potential subclonal mutations was based on mutation variant allele 
frequencies and their accuracies, see Methodological considerations section 
3.3.2. Further, we reported that these mutations could be used for patient-
tailored analysis of MRD with targeted deep sequencing. FACS sorting at 
diagnosis enables identification of leukemia-specific mutations in samples 
with relatively low leukemic cell count. This could otherwise be a challenge 
in a leukemic sample intermixed with normal cells and potential tumor 
heterogeneity. Further, constitutive DNA can be obtained directly at 
diagnosis without additional sampling. The genomes of childhood AML 
harbor very few recurrent mutations and the mutation spectrum is different 
from adult AML, as shown by us and others (15, 140, 174, 175). Thus, the 
use of a global sequencing strategy, like the one we have described, is 
probably necessary to identify somatic mutations in children. The relatively 
cumbersome process of FACS sorting and exome sequencing is likely not 
necessary in adult AML, where sequencing panels targeting genes with 
mutations recurrent in myeloid malignancies have been shown effective to 
identify somatic mutations at diagnosis which can be used for MRD analysis 
(77, 135, 137, 176-179).  
There are also reasons to use several markers of the leukemic cells for 
analysis of MRD, which has been our aim in the papers involving patient-
tailored targeted deep sequencing. Precaution is motivated in cases of 
substantially diverging results in MRD levels between mutations in the same 
sample.  One reason is the potential risk of choosing subclonal mutations as 
outlined above. Another reason is the potential risk of clonal evolution, where 
some mutations have been described to be lost at high frequency during 
treatment, see Introduction, section Clonal evolution. Naturally, not all such 
mutations have been identified yet or can be predicted. Both of these 
scenarios could lead to an underestimation of mutational burden. There is 
also a risk of using preleukemic mutations that are not specific to the 
leukemic cells. Clonal hematopoiesis is found in 5 to 20% of individuals 
older than 70 years. In these individuals, the blood cells harbor premalignant 
mutations at low frequencies, and most common in the genes for epigenetic 
modifiers DNMT3A, TET2 and ASXL1 (DTA) (122, 123). Preleukemic 
mutations could rise in myeloid progenitor cells with selective spread of the 
mutation to parts of the myeloid compartment, but also in HSCs which would 
disseminate the mutation to all directly descending hematopoietic cells. 
Allowing a bit of speculation; when using lymphocytes as constitutive 
genome from a case of the latter scenario for exome sequencing, preleukemic 
mutations could potentially be excluded through bioinformatics filtering if 
the mutation burden is similar for leukemic cells and lymphocytes. More 
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likely, the mutation burden is lower in the lymphoid compartment and the 
preleukemic mutations would be retained in the bioinformatics analysis.  This 
would also be the case when using another source of constitutive DNA (e.g. 
skin or buccal swabs). In the scenario of preleukemic mutations being present 
in parts of the myeloid compartment, including the leukemic cells, the use of 
either lymphocytes or other tissues for constitutive DNA would lead to 
preleukemic mutations being retained in bioinformatics analysis. Indeed, 
when we subjected granulocytes and lymphocytes, isolated from apparently 
healthy donors, to exome sequencing in paper I we identified a few low-
frequency mutations specific to the granulocytes. The mutations did not pass 
the criteria of being MRD suitable. The potential exclusion of preleukemic 
mutations is not problematic as they are unattractive MRD markers, but the 
risk of choosing preleukemic mutations needs to be considered. 
As previously described, DNMT3A mutations are reported to persist in 
complete remission, indicating that they are preleukemic events (45, 46, 180-
182). These studies have shown that persistence of DNMT3A mutations 
confer no prognostic significance. However, a recent study reported that 
patients with at least one persisting mutation in remission (most frequently 
seen in DNMT3A) had worse outcome than patients without persisting 
mutations (183). Further studies are needed to elucidate these conflicting 
results. Another study reported that non-leukemic clones harboring recurrent 
mutations in TP53, DNMT3A, TET2, ASXL1 rapidly increased after induction 
treatment together with concomitant clearance of the AML-associated 
mutations (184). These non-leukemic mutations were identified at low 
frequencies already at diagnosis. In comparison to the population normally 
associated with CHIP, the investigated patients were relatively young and the 
progression of CHIP is slow. The authors propose the rapid expansion (up to 
150-fold in 2 months) implies that chemotherapy confers a competitive 
advantage to HSCs harboring these mutations. The mutations were not 
present in the relapsing clone either, so the potential clinical importance is 
unclear. Mutations in IDH2 have similarly to the DTA-mutations been 
described to persist in long-term remission and are also presumed to be 
preleukemic mutations. Mutations in IDH2 contribute to a block in myeloid 
differentiation via histone hypermethylation. A study of the selective IDH2 
inhibitor Enasidenib, shown to promote myeloid differentiation, in relapsed 
of refractory AML reported that IDH2 mutations (and other cytogenetic 
aberrations) were retained in mature granulocytes from patients in remission 
(185).  
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Germline mutations need to be excluded in some instances, as their VAF will 
not correlate to disease burden, through sequencing of constitutive DNA. The 
ELN recommends sequencing of constitutive DNA when using mutations in 
genes where germline mutations are known to be predisposing of AML 
development as MRD markers (e.g. RUNX1, GATA2, CEBPA) (64). The 
mutations mentioned in this section, frequently seen in AML and MDS, 
should due to their occurrence in non-leukemic cells be avoided as single 
markers for MRD. An exception could perhaps be monitoring after alloHCT, 
where these mutations potentially could be explored as markers for 
reappearing recipient hematopoiesis (186). In molecular MRD analysis, 
germline or preleukemic mutations should be suspected if the VAF remains 
relatively stable despite decreasing blast count (64). 
5.4 INDIVIDUALIZED MRD MONITORING IN 
AML 
The currently used methods for MRD analysis are associated with drawbacks. 
Approximately 20-40% of MFC-MRD negative AML patients relapse, 
suggesting that true low-risk cases cannot reliably be identified using this 
method (13, 110-112). As previously described, RT-qPCR is only applicable 
for the minority of AML patients with recurrent genetic aberrations. To 
increase the applicability of MRD analysis in AML, other methods are 
required. In paper II, we validated our patient-tailored targeted deep 
sequencing assay. Here we showed that this is an accurate and sensitive 
method for MRD analysis of leukemia-specific mutations. The inherent 
sequencing error rate of current NGS platforms calls for efforts to reduce the 
sequencing error background. Several methods to address this have been 
described including bioinformatics processing and the use of reference 
samples. In paper II, we applied a method to correct for sequencing errors by 
the use of reference samples, reaching a limit of detection of VAFEC 0.02%. 
(141). Others have pursued the use of unique molecular identifiers (UMIs) 
for barcoding of each DNA molecule before PCR amplification of the 
sequencing library (135, 137, 176, 187, 188). This is a process which enables 
identification and exclusion of reads with PCR or sequencing errors. Thol et 
al. demonstrated a detection limit of VAF 0.005% for two mutations in the 
genes IDH1 and IDH2 in a dilution series experiment using UMIs (135). In 
the cohort of 96 AML patients MRD positive before alloHCT, analyzed by 
custom NGS analysis, the VAF ranged between 0.016% and 4.91%, i.e. the 
lowest measurement was not that different from the LOD of VAFEC 0.02% 
which we have described. They reported that MRD positivity before alloHCT 
was highly predictive of outcome. A combination of sequencing error 
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reducing approaches is likely the way forward to reach levels of detection for 
targeted deep sequencing comparable to those for quantitative PCR. The 
cutoff for MRD positivity in the studies below exploring NGS based MRD 
analysis of patient-specific mutations in adult AML are hence generally 
higher than for qPCR-based assays.  
The prognostic importance of clearance of patient-specific mutations has 
been shown for adult AML by several research groups. Hirch et al. reported 
that persistence of two or more mutations in more than 0.4% of cells in 
remission samples was associated with decreased overall survival (137). 
Jongen-Lavrencic et al. interestingly reported that the combined use of MFC-
MRD and sequencing MRD in CR confer additive prognostic value for 
relapse rate and overall survival as compared to either method alone (177). In 
a study by Gaksch et al., analysis of mutation clearance post-consolidation 
showed that persistence of mutations (MRD positivity defined as VAF 
>0.5%, DNMT3A mutations excluded) was significantly associated with 
shorter RFS, but not OS. MRD positivity was in multivariable analysis, 
together with age, leukocyte count and genetic risk shown to be predictive of 
relapse (176). Press et al. used a 42-gene NGS sequencing panel to analyze 
MRD within 30 days before alloHCT. The CIR post-transplant was 
significantly higher in patients with pre-transplant MRD positivity (VAF 
>0.5%). MRD positivity was also shown to be an independent predictor of 
relapse after adjustment for TP53 mutations and conditioning regimen (179). 
In a study with similar setup (NGS panel for identification of recurrent 
mutations at diagnosis followed by custom amplicon sequencing of follow-up 
samples), Thol et al. reported detection of recurrent mutations in a cohort of 
adult AML before alloHCT (MRD positive samples ranging between VAF 
0.016% - 4.91%) to be an independent predictor of CIR (135). In conclusion, 
these studies show the prognostic potential of targeted deep sequencing and 
promise a broader applicability of MRD analysis in AML. 
5.5 NGS – BASED MRD ANALYSES IN AML 
WITH MUTATED NPM1 
As described previously, insertions in NPM1 are frequently recurrent in 
AML. Thirty percent of adult AML have a mutation in NPM1, for which 
analysis is included in clinical routine. Mutations in NPM1 have been 
reported as reliable MRD markers, and are extremely suitable targets for deep 
sequencing due to mutation heterogeneity.  There is a plethora of recurrent 
insertion mutations in exon 12 of NPM1, though some are more frequent. A 
major advantage of targeted deep sequencing MRD analysis of NPM1 over 
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standard qPCR assays is the possibility to simultaneously analyze all 
recurrent insertion mutations. Consequently, NGS based MRD analysis of 
NPM1 has been investigated in association with patient outcome.  
Patkar et al. used NGS MRD to analyze NPM1 during treatment (post-
induction and post-consolidation) of AML and reported that MRD positivity 
(defined as <11og10 reduction between time points) was the most important 
independent prognostic factor predictive of OS. They showed a significant 
concordance between NGS MRD and qPCR for patients with NPM1 type A 
mutation (136). In a study performed by Jongen-Lavrencic et al. an NGS 
targeted gene panel was used to monitor MRD in AML patients in CR for 
who at least 1 mutation were identified at diagnosis. The most frequently 
occurring mutation was in NPM1 and they reported that persistent mutations 
in remission were associated with decreased RFS and OS (177). A Spanish 
group investigated the use of targeted deep sequencing MRD analysis in 
AML patients with NPM1 insertions or SNVs in FLT3, IDH1 and IDH2 post-
induction and post-consolidation. In this study, MRD >0.1% post-induction 
was associated with significantly decreased OS, but significance was not 
reached for DFS. MRD levels >0.025% post-consolidation was associated 
with both decreased OS and DFS. Survival analyses were also performed on 
NPM1 and SNVs separately with similar results. In multivariable Cox 
analysis, increased age, FLT3-ITD, and MRD positivity were associated with 
higher risk of death. Only MRD positivity was associated with increased risk 
of relapse (189).  
In paper III, we reported MRD positivity after alloHCT determined with deep 
sequencing of NPM1 to be an independent predictor of relapse post-
transplant. This result is in line with previous studies showing that MRD 
status post-transplant determined with MFC-MRD (86, 87) or RT-qPCR (25, 
98) of NPM1 is a strong predictor of relapse. Our finding is supported by 
Zhou et al. who analyzed NPM1 using NGS MRD before and after alloHCT. 
That study showed that MRD positivity after alloHCT is associated with 
increased risk of relapse (190, 191).   
5.6 ddPCR FOR ANALYSIS OF MRD 
Another platform for high-sensitivity MRD analysis of somatic mutations is 
droplet digital PCR (ddPCR). This is a method that uses emulsion PCR for 
analysis of individual DNA molecules amplified in droplets. Using specific 
fluorescent probes for the wildtype and mutated target sequence, a digital 
(yes/no) signal is acquired from each droplet. This makes quantification 
possible without a need for calibration curves. Studies comparing MRD 
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results from ddPCR and RT-qPCR using either Ig/TCR rearrangements in 
ALL or PML-RARA transcripts in APL found concordant results for the two 
methods (192, 193). Regarding use of ddPCR MRD analysis for detection of 
patient-specific mutations in AML, Parkin et al. analyzed somatic mutations 
in CR and reported better 3-year RFS for patients achieving a reduction in 
mutation burden <0.01% in CR than for those who did not (33% vs 81%) 
(194). Analysis of somatic mutations with ddPCR has also been investigated 
in circulating cell-free DNA after alloHCT in AML/MDS (median detection 
limit 0.04%) (186). Mutation persistence in serum one and three months after 
transplantation was associated with higher CIR, as was mutation persistence 
in matched BM samples. In this setting (post-alloHCT), also persistence of 
the preleukemic DTA mutations had prognostic effect on CIR. Mencia-
Trinchant et al. explored a multiplex strategy for NPM1 mutations for ddPCR 
MRD measurements, in an effort to broaden the applicability of the assay 
(195). A high sensitivity was reported. However, the number of NPM1 
mutations possible to multiplex in such an assay is limited and with higher 
background than for the type specific assays. MRD positivity before alloHCT 
as determined with ddPCR of NPM1 (using multiple mutation specific 
probes) was shown by Bill et al. to be an independent negative prognostic 
marker in a cohort of 51 patients with adult AML with NPM1 mutation (196). 
5.7 MRD SURVEILLANCE AFTER END OF 
TREATMENT 
RT-qPCR is only applicable for the fraction of AML patients with recurrent 
cytogenetic aberrations, whereas targeted deep sequencing using somatic 
mutations as MRD markers can be applied for the majority of patients. In 
paper II, we analyzed corresponding PB samples for patients who were 
determined MRD positive (<VAFEC 5%) in BM and showed that mutations 
could be detected also in PB for all patients with VAF >0.1% in BM. This 
suggested that deep sequencing also could be used to monitor PB, a notion 
that was extended in paper IV. In paper IV, we demonstrated the potential of 
patient-tailored targeted deep sequencing during follow-up. We could detect 
leukemia-specific mutations in PB before hematological relapse in almost all 
investigated patients. The first MRD positive sample preceded hematological 
relapse with a median of 90 days. This suggests that the methodology could 
be used for MRD surveillance after end of treatment for early detection of 
relapse and as a basis for studies on MRD guided preemptive treatment. 
Others have used RT-qPCR analysis of fusion transcripts or mutated NPM1 
for leukemia surveillance during follow-up and shown that molecular relapse 
heralds the hematological relapse (91, 103, 104, 168). Based on this, the ELN 
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has defined molecular relapse using RT-qPCR as one log10 increase between 
two MRD positive samples in a patient who previously tested negative (64). 
When we applied the ELN definition described above to the nine relapsed 
patients included in paper IV, a one log10 increase only occurred for one 
patient before hematological relapse.  The window of detection is narrower 
for targeted deep sequencing than for RT-qPCR, specifically 3.25 log10 
increases from the LOD of VAFEC 0.02% to the maximum theoretical VAFEC 
of 50% for heterozygous mutations. A VAFEC doubling between two MRD 
positive samples in a patient who previously tested negative occurred in 6/9 
patients at a median of 80 days before hematological relapse and might be a 
more appropriate definition of molecular relapse in targeted deep sequencing 
MRD analysis. Relapse kinetics has been described using RT-qPCR for 
different subtypes of AML. For the few patients so far analyzed in paper IV, 
the MRD doubling time was similar to previous reports on fusion transcripts. 
In our study, two patients with CBFB-MYH11 had a median doubling time of 
28 days and two patients with KMT2A-rearragments a median doubling time 
of 11 days. Ommen et al. reported median doubling times of 36 days for 
CBFB-MYH11 and 12 days for KMT2A- rearrangements for RT-qPCR 
analyses of BM (103, 104).   
In conclusion, targeted deep sequencing is a promising novel technique for 
MRD analysis in AML, enabling sensitive and personalized leukemia 
surveillance for patients currently lacking molecular markers for MRD. 
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6 CONCLUDING REMARKS & FUTURE 
PERSPECTIVES 
As the landscapes of clonal heterogeneity and evolution of AML are 
unraveled, the suitability of different mutations as patient-specific MRD 
markers will become clearer. Already at this point it is clear that mutations in 
some genes are less suitable as MRD markers due to frequent loss during 
treatment (e.g. FLT3, NRAS, KRAS, IDH1, IDH2) or due to persistence in 
long-term remission (e.g. DNMT3A, TET2, ASXL1), whereas mutations in 
other genes are more suitable (e.g. NPM1). Exome-sequencing was 
performed on diagnostic and relapse samples in several of the included 
studies, with the objective to identify MRD-suitable patient-specific 
mutations in AML patients. These markers were chosen based on criteria that 
did not concern gene class or predicted pathological effect of the mutation.  
This data set can be further exploited in the future. Gene ontology analysis 
can be performed to investigate if gene mutations involved in certain 
pathways are more common at diagnosis and if mutations in some genes are 
more stable than others from diagnosis to relapse. The relative stability of 
predicted pathogenic mutations versus passenger mutations can also be 
explored. This can add information to the current literature on the MRD-
suitability of different genes. Further, identified novel recurrent mutations 
can be tested in functional studies using in vitro or in vivo experimental 
setups.     
The results from paper II suggested that targeted deep sequencing MRD 
analysis is more sensitive than MFC-MRD, but this needs to be confirmed in 
a larger patient material. An ongoing project within our research group 
therefore aims to evaluate if patient-tailored targeted deep sequencing is more 
sensitive and applicable than MFC for MRD assessment during treatment in 
childhood AML. Patient-tailored targeted deep sequencing will in this study 
be performed on samples from the three time points at which MFC-MRD 
analyses are performed in the NOPHO-DBH AML-2012 treatment protocol 
(day 22 after start of induction treatment, before start of the second induction 
course and before consolidation). The predictive value of the MRD results on 
outcome will be tested. If positive, targeted deep sequencing might qualify as 
a risk stratifying tool in a future version of the childhood AML trial protocol.  
In paper III, we reported that targeted deep sequencing covers all recurrent 
insertions in exon 12 of the NPM1 gene using a single assay. The RT-qPCR 
assay commonly used in clinical routine is specific for the NPM1 type A 
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mutation. Due to the high degree of similarity between different NPM1 
insertions, the assay can detect presence of other insertion types, but it cannot 
be used for reliable MRD quantification. Targeted deep sequencing will 
therefore be highly suitable for molecular MRD analysis of patients with 
non-type A insertions in NPM1. Introduction of several different methods for 
patients with NPM1 mutations calls for comparisons between methods, which 
is also ongoing in our group.  
It has been reported that different subtypes of AML have very varying 
relapse kinetics, where the time from molecular relapse to hematological 
relapse ranged between a few weeks to several months. To be able to conduct 
studies on MRD guided preemptive treatment of early relapses using 
individualized molecular methods, the relapse kinetics of different mutation 
types need to be elucidated. In paper IV we describe how the relapse kinetics 
of patient-specific mutations vary between groups of patients with different 
cytogenetic aberrations. Before a new methodology can be used for 
monitoring, also patients who do not relapse need to be studied. Also, as 
ddPCR also has shown promise for assessment of mutation burden, use of 
both methods in parallel would be of interest. Both ddPCR and deep 
sequencing can be used for MRD analysis at the DNA level by determination 
of residual variant alleles, but it remains to be investigated how these 
methods compare. Likely they will be shown to be complementary tools. As 
the reagents for ddPCR are cheaper, it could serve as a cost-effective 
alternative for quantification of identified specific genetic lesions. Deep 
sequencing is more useful than ddPCR for quantification of mutations in 
hotspot regions in the genome, in cases where the mutated sequence 
frequently differ. In this setting one assay is sufficient using deep sequencing, 
whereas ddPCR would require multiple mutation specific probes, as 
previously described for exon 12 of the NPM1 gene. Still, previously 
undescribed mutations would not be identified. 
 There is clear evidence that MRD is a strong and independent marker of 
prognosis in AML. In addition, there is retrospective data which suggests that 
MRD status surpasses the current principal predictors of outcome, i.e. 
mutational status. Studies on individualized molecular MRD analyses, 
performed by our and other research groups, have shown promising results. 
Such methods will enable sensitive MRD analysis for essentially all AML 
patients. Perhaps the now existing technologies for MRD analyses under 
optimized conditions are sufficient tools for determination of treatment 
response and surveillance in AML. When and how to test as well as how to 
act on the results however need to be clarified. To determine the full potential 
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of MRD directed therapy in AML, large randomized controlled trials for 
MRD based treatment strategies are necessary. 
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